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BacqroUDd 
As a recipient otthe Univenity ofTenucssee. Knoxvillc·s Whittle Scholarship. one ormy 
requirements for graduation is the completion of a University Honors Program senior project As outlined in 
the University Honors Program Student H andboo/c. the ~uior project is "lUI opportunity for each honors 
student to become ensased in reaearcb or creative activity tbal marks a capstone of the undergraduate 
experience." Although a large portion of senior projects relate 10 the studcntts field of study, the University 
Honors DepQJ1menl does not require tllat a student complete hiSlher project in hiSlher academic major. This 
loose constraint alloWl'i stu.dc:nb to explore new areu and &0 learn things they otherwise would not have studied 
in schooL BecaWie of the extreme scope these senior projects can be focused on, the University Honors 
Department bas inCOrporllted Il few general requirements to qualify Il student's work 6.0; a senior project. 
The fu-st requirement tor a student to complete is to select and recruit 11 fllCulty mentor. As the 
primary purpose of the faculty mentor is to assist and guide the .student along his/her senior project. a faculty 
mentor should be knowledgeable in tha project's subject and Ilcccssiblc to the student. Sclt.'Cting a faculty 
mentor is a crucial part of the senior project for helshe will have to approve the initial senior project 
prospectus. to review and edit drafts ofthc project, and to approve the final draft for submission as a senior 
project After selecting Il faculty mentor. the second requirement of a senior project is to enroll in the senior 
projt:ct 15(.:mmar, a one-how- clllSS taught by the University Honors' dcporLmenL head. Although this class is 
designed aroWld the senior project, its empbuis is not on completmg the senior prQjecl. but rather to as..;st 
students in selecting. researching, aDd beginning their senior projects, to expose students to various other 
academic interests. and &0 provide students the opportunity to deliver professional anu presentations, 
Recosnjzing that many academic majors also require some type of senior resePlcn or senior design project to 
culminate a student·s underaraduate experience. the University Honors Department provides a method, listed 
in the University Honors Program Student Handbook, to complete both requirements with a single project: 
"If a student wishes to use some part of a senior non-honors or group project as the student's senior hOllors 
project, the additional effort should be clearly defmed on the • Senior Project Approval,' and pennission should 
be obtuincd from the University HOllars Office,"' Upon completion of these requirements for a University 
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Honors senior projecl, students should finish a work that can be placed upon their resumes and discussed with 
prospccti ve employers or admissioo.s boards. 
Purpulc 
The purpose of this paper is 10 ada.pt my nuclear engineering senior design project. UDesign of a 
Clinical Boron Neutron Capture Therapy Treatmenl Facility." to the constraints ond qualifications necessary to 
~tisry the requirements of a University Honors Program"s senior project In order to accomplish this goal. the 
remainder of this paper will focus on explainina the project in a non-technical fashion. the mclbods used by my 
group to complete the design project. my personal contributions to the design project. and my insights and 
opinions on the design project 
DOIign of a Clinical Boroo Neutron Capture Thenpy (BNC1) Treatment Facility - a projeet 
explanation 
8NCT is an ideo concerning the treatment and destruction offormerly inoperable tumors. Patients un: 
given a solution of boron which is readily absorbed by and concentrated in the maHgnant tumor cells. Upon 
being exposed to Q stream of neutrons. a boron atom will absorb a neutron and split into two particles. The 
separation. or fission. of the boron atom will generate enough energy to kill the malignant cell without harming 
the surrounding bealthy cells. However. this process is far more difficult than it first appears. Not only must a 
neutron collide with a boron atom, that neutron must have a CCltain energy level when the collision occurs. If 
the energy level of the neutron is too high or too low, the desired separation of the boron atom will not occur. 
As neutrons must not only engage boron atoms but engage them i.1l a specific energy range. my design 
proj ~ct focuses primarily on changing the energy of the neutrons when they AlTAVe at the boron atoms. and 
secondly on designing a BNCT treatment center layout As one possible source of neutrons for BNCT. Oak 
Ridge National Lab's Tower Shielding RePCtor (TSR}.lies within a short drive nom Knoxville, my class's goal 
would be [0 dcsjgn the trcalrnent facility lit the TSR and apply the IIbove foci. The results tlIld further 
2 
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explantttion of the project is contained in our final draft. "Design of a Clinical Boron Neutron Capture Therapy 
Treatment Facility. ,. 
Group Method! to Facilitate Project Completion 
flI 006/008 
Selected from the students cw'OUed in the Sprins 1996 section of Nuclear Engineering 472~ my design 
group consisted of six students; Chet Rwnsey, Cindy Maples. Don Marsh. Anne Robinson-Silber, Randy 
Hooker, und myself. Once we were assigned to groups. our first tASk was to decide how we wanted to approach 
UUs project. Following much discussion. we decided that we would begin oW" research by gaining an 
undcrslunding of the history behmd BNCT IUld the TSR. Once comf'orw.ble with the bllSic tenninology 
WlSociatcci with BNCT and the TSR, we besou our second task. deciding upon the scope and orsouization of 
our work. Over the COlD"SC of the next few weeks. we nllITowed down the scope of OUT project to include the 
design of a shutter and collimator system for the ISK. &9 well as a design for the treatment facility. Eventually, 
we broke it down into fifteen basic elements. listed in section 1.4 of "Dcsisn of u Clinical Boron Neutron 
Capture Therapy Treatmenr Facility." We then assigned group members to work in vru'ious categories 
according to hislher interests and skills. Around this time in the project we decided that ill order to promote 
efficiency amol1S the group that we would ueed to appoint group leuder. Although the group leader would be 
expected to assist IIIld to assign work to other team members, he/she would also have to pl..'Ttorm duties of 
hislher own. which weighed heavily upon our decision when electing 8 member to this position. Eventually, 
Chet Ramsey was uppointed our group leuder. After breaking down the projcct and uSbigning group members 
to specific tasks, the final, and most difficult aspect, of our project was to accumulute all of tbe infonnation we 
had collected and insert it into a report fashion. This proved to be troublesome as combillin& the tbouahts und 
ideas of six unique individuals is a combination of much time and putience. 
Penonal Contribution" to Ih. Gro"p Project 
In addition to perfonning some coqunon tasks of the group (e.g., background research. report editing. 
und report writing). I concentrated my efforts primarily on Lbe economic, licensing. and mechanical design 
3 
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aspects of our desip. project. Obtaining estimates OD the construction of the BNCT facility. discussing and 
detennining necessary equipment and personnel for the facility. collecting estimuld on the equipment und 
personnel, determining approximate cost of treatment, estimating start-up. mWntcnmcc, operating. and 
decommissioning costs, and determining the cost of licensing the facility were primary interests in the 
economic analysis of our design. In order La accomplish these tasks. I bad to COlltoct multiple individuals who 
were knowledgeable on many different subjects. For instance. to obtain an estimate for the construction of our 
proposed facility. I discussed the floor plans with Randy and Cindy to determine the absolute necessary 
components for conS1rUCtion (e.g., the treatment room must have concrete walls) and then spoke with different 
contrllctors who would be able to bid on SlWb a job. In order to determine what equipment and personnel 
would be necC5.'ml'Y to operate such a facility. I spoke with several chemists, doctors, and nurses who provided 
yaluable opinion:;. After deciding whot we needed, I then had to contact distributors of the equipment to obtain 
estimates. Much of my time was Itlso spent discussing the estimated sturt-up, maintenance. shutdo'Wtl. and 
deconunissioning costs with sevetal individuals at Tennessee Center tor Resetirch and Development. 1'1 
Knoxville company CWTently working on a feasibility study for a BNCT treatment facility at the TSR. 
In addition to the economic research, I invested a great deal of time in (&!Sew-ching the licensing 
a.<;pects of our design. The majority of this research was done over the phone, conversing with individuals at 
the Oak Ridge NiltionPl L{1b. the DelllU1ment ofEnel'gy. W'ld other govemment organizations. In addition to the 
multipJe conversations, 1 spent time reading stIme government regulations that were delermined Lo be of 
primtuy importance to our design. Although much research W{I.$ put into the licensing necessary to operate our 
proposed BNCT treatment facility, a lurse portion WPS left for future work wltil greoter detaiJs about the fACility 
are available. 
Not all of my contributions to the proj ect were in the form of pW'C research and persistence. as I was 
also Involved with the mechanical design of the shutter/collimator system. This gove me an opportunity to 
implement some of the critical thinking skills that are so necessary to engineering, Alk'f discussing the pros 
and COPS ofmWlY idcu. we decided that rather than modify the existing system 81 the TSR, we would design It 
4 
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entirely new ~j'5tem. Mucb ofmy personal contribution to this facet of the design projcct revolved aroWld. 
intrinsic safety features and stability of the system. 
Opinion! and IDsigbb about tbo DelllU Projeet 
III 008/008 
Overall. I fOWld this design project to be 1m interesting IlI1d informative endeavor. Although we did 
not have the opporlunity to cboo..~ oW' own project, designing a ENeT treatment facility was an excellent 
choice because it was able to combine traditional facets of nuclear engineering (e.g .• neutron transport) with the 
health physics/medical side of nuclcur engineering. This not only peaked dift'erent mterests in our group_ but 
also forced us to become more dynamic in our thinking. Requiring cvcry1hing from libruy research to 
computer simulations to personal inquiries. the projcct look the Conn of Ureal world" engineering. 
Although the technical skills developed and information acquired I1lay prove useful in the future, the 
most important skills developed dw'ing this project come from the challenge of six individuals attempting to 
work together as one team. Through this experience. I gained insishl on how important corrununication was to 
the group's success. how different individuals express their thoushts and opinions in different WIl}'S. how 
utilizing the talents of different individuals can lead to grealer efficiency. how diJicrcnl people arc productive in 
different settings, and many other things. Participatmg in this group gove me: fW1her conviction as to the 
importance of being able to communicate and listen LO others, no matter what field I enLer. 
Even with the success of my project. ifl had to do it again there arc a few ChWlgt.--S I would 8ltempt to 
implement. First of aU. r would definitely begin the research earlier. Althouib a last minute alteration may not 
be Ilble to be avoided, I can not stress enough the importance of pllCing yourself throughout the semester. Not 
only wm this lend Lo a project of higher quality. il will also make the project more \'-njoyablu. Scroondly. I would 
attempt Lo get involved in almost all of the laccLs of the: projcct. Once ag&in. the greater YOUt involvement in 
the projL"Cl. the more you will enjoy and learn from it. Finally. 1 would not hesitate {O contaot people who have 
oll'Crcd Lo help you and even those that have not I WDS smpriscd at how much information CUll be obtained 
with u lin1c cxplanation ot'my project along with a tew "please md thlillk you"s. More times than not people 
were willing to go out oftbeir wily to help me with the project 
5 
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Background 
As a recipient of the University of Tennessee, Knoxville's Whittle Scholarship, one of my 
requirements for graduation is the completion of a University Honors Program senior project. As outlined in 
the University Honors Program Student Handbook, the senior project is "an opportunity for each honors 
student to become engaged in research or creative activity that marks a capstone of the undergraduate 
experience." Although a large portion of senior projects relate to the student's field of study, the University 
Honors Department does not require that a student complete his/her project in his/her academic major. This 
loose constraint allows students to explore new areas and to learn things they otherwise would not have studied 
in school. Because of the extreme scope these senior projects can be focused on, the University Honors 
Department has incorporated a few general requirements to qualify a student's work as a senior project. 
The first requirement for a student to complete is to select and recruit a faculty mentor. As the 
primary purpose of the faculty mentor is to assist and guide the student along hislher senior project, a faculty 
mentor should be knowledgeable in the project's subject and accessible to the student. Selecting a faculty 
mentor is a crucial part of the senior project for he/she will have to approve the initial senior project 
prospectus, to review and edit drafts of the project, and to approve the final draft for submission as a senior 
project. After selecting a faculty mentor, the second requirement of a senior project is to enroll in the senior 
project seminar, a one-hour class taught by the University Honors' department head. Although this class is 
designed around the senior project, its emphasis is not on completing the senior project, but rather to assist 
students in selecting, researching. and beginning their senior projects, to expose students to various other 
academic interests, and to provide students the opportunity to deliver professional oral presentations. 
Recognizing that many academic majors also require some type of senior research or senior design project to 
culminate a student's undergraduate experience, the University Honors Department provides a method, listed 
in the University Honors Program Student Handbook, to complete both requirements with a single project: 
"If a student wishes to use some part of a senior non-honors or group project as the student's senior honors 
project, the additional effort should be clearly defmed on the 'Senior Project Approval: and permission should 
be obtained from the University Honors Office." Upon completion of these requirements for a University 
1 
Honors senior project, students should finish a work that can be placed upon their resumes and discussed with 
prospective employers or admissions boards. 
Purpose 
The purpose of this paper is to adapt my nuclear engineering senior design project, "Design of a 
Clinical Boron Neutron Capture Therapy Treatment Facility," to the constraints and qualifications necessary to 
satisfy the requirements of a University Honors Program's senior project. In order to accomplish this goal, the 
remainder of this paper will focus on explaining the project in a non-technical fashion, the methods used by my 
group to complete the design project, my personal contributions to the design project, and my insights and 
opinions on the design project. 
Design of a Clinical Boron Neutron Capture Therapy (BNCT) Treatment Facility - a project 
explanation 
BNCT is an idea concerning the treatment and destruction offonnerly inoperable tumors. Patients are 
given a solution of boron which is readily absorbed by and concentrated in the malignant tumor cells. Upon 
being exposed to a stream of neutrons, a boron atom will absorb a neutron and split into two particles. The 
separation, or fission, of the boron atom will generate enough energy to kill the malignant cell without hanning 
the surrounding healthy cells. However, this process is far more difficult than it first appears. Not only must a 
neutron collide with a boron atom, that neutron must have a certain energy level when the collision occurs. If 
the energy level of the neutron is too high or too low, the desired separation of the boron atom will not occur. 
As neutrons must not only engage boron atoms but engage them in a specific energy range, my design 
project focuses primarily on changing the energy of the neutrons when they arrive at the boron atoms, and 
secondly on designing a BNCT treatment center layout. As one possible source of neutrons for BNCT, Oak 
Ridge National Lab's Tower Shielding Reactor (TSR), lies within a short drive from Knoxville, my class's goal 
would be to design the treatment facility at the TSR and apply the above foci. The results and further 
2 
explanation ofthe project is contained in our final draft, "Design of a Clinical Boron Neutron Capture Therapy 
Treatment Facility." 
Group Methods to Facilitate Project Completion 
Selected from the students enrolled in the Spring 1996 section of Nuclear Engineering 472, my design 
group consisted of six students: Chet Ramsey, Cindy Maples, Don Marsh, Anne Robinson-Silber, Randy 
Hooker, and myself Once we were assigned to groups, our first task was to decide how we wanted to approach 
this project. Following much discussion, we decided that we would begin our research by gaining an 
understanding of the history behind BNCT and the TSR. Once comfortable with the basic terminology 
associated with BNCT and the TSR, we began our second task, deciding upon the scope and organization of 
our work. Over the course of the next few weeks, we narrowed down the scope of our project to include the 
design of a shutter and collimator system for the TSR, as well as a design for the treatment facility. Eventually, 
we broke it down into fifteen basic elements, listed in section 1.4 of "Design of a Clinical Boron Neutron 
Capture Therapy Treatment Facility." We then assigned group members to work in various categories 
according to hislher interests and skills. Around this time in the project we decided that in order to promote 
efficiency among the group that we would need to appoint group leader. Although the group leader would be 
expected to assist and to assign work to other team members, he/she would also have to perform duties of 
hislher own, which weighed heavily upon our decision when electing a member to this position. Eventually, 
Chet Ramsey was appointed our group leader. After breaking down the project and assigning group members 
to specific tasks, the final, and most difficult aspect, of our project was to accumulate all of the information we 
had collected and insert it into a report fashion. This proved to be troublesome as combining the thoughts and 
ideas of six unique individuals is a combination of much time and patience. 
Personal Contributions to the Group Project 
In addition to performing some common tasks of the group (e.g., background research, report editing, 
and report writing), I concentrated my efforts primarily on the economic, licensing, and mechanical design 
3 
aspects of our design project. Obtaining estimates on the construction of the BNCT facility, discussing and 
detennining necessary equipment and personnel for the facility, collecting estimates on the equipment and 
personnel, determining approximate cost of treatment, estimating start-up, maintenance, operating, and 
decommissioning costs, and determining the cost of licensing the facility were primary interests in the 
economic analysis of our design. In order to accomplish these tasks, I had to contact multiple individuals who 
were knowledgeable on many different SUbjects. For instance, to obtain an estimate for the construction of our 
proposed facility, I discussed the floor plans with Randy and Cindy to determine the absolute necessary 
components for construction (e.g., the treatment room must have concrete walls) and then spoke with different 
contractors who would be able to bid on such ajob. In order to determine what equipment and personnel 
would be necessary to operate such a facility, I spoke with several chemists, doctors, and nurses who provided 
valuable opinions. After deciding what we needed, I then had to contact distributors of the equipment to obtain 
estimates. Much of my time was also spent discussing the estimated start-up, maintenance, shutdown, and 
decommissioning costs with several individuals at Tennessee Center for Research and Development, a 
Knoxville company currently working on a feasibility study for a BNCT treatment facility at the TSR. 
In addition to the economic research, I invested a great deal of time in researching the licensing 
aspects of our design. The majority of this research was done over the phone, conversing with individuals at 
the Oak Ridge National Lab, the Department of Energy, and other government organizations. In addition to the 
multiple conversations, I spent time reading some government regulations that were determined to be of 
primary importance to our design. Although much research was put into the licensing necessary to operate our 
proposed BNCT treatment facility, a large portion was left for future work until greater details about the facility 
are available. 
Not all of my contributions to the project were in the form of pure research and persistence, as I was 
also involved with the mechanical design of the shutter/collimator system. This gave me an opportunity to 
implement some of the critical thinking skills that are so necessary to engineering. After discussing the pros 
and cons of many ideas, we decided that rather than modifY the existing system at the TSR, we would design a 
4 
entirely new system. Much of my personal contribution to this facet of the design project revolved around 
intrinsic safety features and stability of the system. 
Opinions and Insights about the Design Project 
Overall, I found this design project to be an interesting and informative endeavor. Although we did 
not have the opportunity to choose our own project, designing a BNCT treatment facility was an excellent 
choice because it was able to combine traditional facets of nuclear engineering (e.g., neutron transport) with the 
health physics/medical side of nuclear engineering. This not only peaked different interests in our group, but 
also forced us to become more dynamic in our thinking. Requiring everything from library research to 
computer simulations to personal inquiries, the project took the form of "real world" engineering. 
Although the technical skills developed and information acquired may prove useful in the future, the 
most important skills developed during this project came from the challenge of six individuals attempting to 
work together as one team. Through this experience, I gained insight on how important communication was to 
the group' s success, how different individuals express their thoughts and opinions in different ways, how 
utilizing the talents of different individuals can lead to greater efficiency, how different people are productive in 
different settings, and many other things. Participating in this group gave me further conviction as to the 
importance of being able to communicate and listen to others, no matter what field I enter. 
Even with the success of my project, if I had to do it again there are a few changes I would attempt to 
implement. First of all, I would definitely begin the research earlier. Although a last minute alteration may not 
be able to be avoided, I can not stress enough the importance of pacing yourself throughout the semester. Not 
only will this lead to a project of higher quality, it will also make the project more enjoyable. Secondly, I would 
attempt to get involved in almost all of the facets of the project. Once again, the greater your involvement in 
the project, the more you will enjoy and learn from it. Finally, I would not hesitate to contact people who have 
offered to help you and even those that have not. I was surprised at how much information can be obtained 
with a little explanation of my project along with a few "please and thank you"s. More times than not people 
were willing to go out of their way to help me with the project. 
5 









University of Tennessee, Knoxville 
April 17, 1996 
American Nuclear Society 
Student Design Competition 
F acuIty Advisor 
Dr. H. L. Dodds, Jr. 
Nuclear Engineering Department 
The University of Tennessee, Knoxville 
Dedication 
We would like to dedicate our work to the 5415 people that die every year from 
Glioblasoma Multiform 
Acknowledgments 
We would like to thank the following individuals for their time and expertise in 
speaking to our design class: G. Flanagan, D. Ingersoll, C. Slater, and W. Hill of Oak 
Ridge National Laboratories, G. Dilworth and C. Wilson of the Tennessee Center for 
Research and Development, G. Kabalka of the University of Tennessee Chemistry 
Department and R. A. Lillie. We would also like to thank R. Pevey and S. Goluoglu for 
their tireless efforts and assistance with DOR T and other computer codes. An additional 
thanks to C. Wilson for his input in the economic analysis and to G. Kabalka for assistance 
in the medical facility design. Our thanks to T. Kerlin for reviewing our original report 
draft. Finally to H. L. Dodds, our sincere gratitude for his efforts in coordination and 
organization of our project. 
Abstract 
The goal of this design project is to develop a conceptual design ofa clinical 
facility for Boron Neutron Capture Therapy that utilizes Oak Ridge National Laboratory's 
Tower Shielding Reactor as the neutron source. The primary focus of this report is to 
develop an overall facility design as well as designs for a conceptual beam collimator and 
beam shutter. Additionally, system safety and facility economics are addressed. 
The overall facility design includes treatment rooms::> a confinement building, and 
supporting medical facilities. The medical facilities support the outpatient treatment of 
cancer patients in a comfortable environment. The treatment room and confinement 
building provide protection for the patients, environment, and personnel during normal 
and abnormal operations. Facility economics are evaluated for startup, maintenance::> 
operating, and decommissioning costs as well as income generated from treating patients. 
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In the United States 1,515 people die every day from all types of cancer.22 At 
present, the only way to survive is with an effective treatment, but with some forms of 
cancer there is none. An ideal treatment for cancer would ignore normal cells while 
simultaneously seeking out and destroying rapidly dividing cells.3 With today's medical, 
chemical, and nuclear technology, a procedure based on these principles has been 
successfully administered. 
Boron neutron capture therapy (BNCT) is a treatment that brings together two 
components that individually have little effect on normal tissue. The first component is a 
chemical compound that contains the stable isotope boron-I 0, and the second is a beam of 
neutrons. When injected into the body, the chemical compound will concentrate in 
cancerous cells. After a short period of time, the boron compound is biologically removed 
from normal tissue. When the boron-I 0 absorbs neutrons it subsequently decays by alpha 
emission. The alpha particle and the recoiling lithium atom deposit most of their energy 
inside the cell containing the original boron.2 The result of this reaction is a deadly 
radiation field of heavy particles localized to tumor cells as shown in Figure 1. 1. ·17 
Although treatment such as surgery, chemotherapy, and radiation have successfully 
Figure 1. 1 Schematic of the Boron-IO Neutron 
Interaction 
treated many types of cancer, there are 
some forms for which BNCT is the only 
solution. One of the most highly malignant 
and resistant of all cancers is Glioblasoma 
Multiform (GBM). GBM is a cancer of 
the glial supportive tissue of the central 
nervous system (CNS). Glial cells, which 
make up over 90 percent of the CNS, 
provide chemical and physical support to neurons. Unlike neurons, glial cells are extremely 
susceptible to cancer because they are constantly undergoing mitosis. The standard 
treatment for GBM is an external beam of 4 to 6 MeV X-rays, given in doses of 
approximately 60 Gy administered in fractions of 1.8 to 2.0 Gy daily five days a week. 31 
Unfortunately, this method destroys much of the intervening healthy brain tissue in the 
beam path, and unless every cancer cell is killed, there is a possibility that the cancer will 
reestablish itself The median survival rate for treated GBM ranges from eight to fourteen 
months while untreated GBM results in a median survival rate of three months. 
During 1995, approximately 323,000 people in the United States died from brain, 
colon, skin, lung, breast, and prostrate cancer, all of which could have been treated with 
BNCT. Ifproven effective:> over 90,000 patients yr-l could qualify for BNCT. The life 
extension and higher quality of life beyond conventional treatments could potentially 
return over $73 billion to the U.S. Treasury over a 10 year period. 14 
2 
1.2 Design Objectives 
The goal of this design project is to develop a conceptual design of a clinical 
facility for Boron Neutron Capture Therapy that utilizes Oak Ridge National Laboratory's 
(ORNL) Tower Shielding Reactor (TSR) as the neutron source. The primary focus of this 
proj ect is to develop an overall facility design as well as designs for a conceptual beam 
collimator and beam shutter. Additionally, system safety and facility economics will be 
addressed by the final design. 
The beam collimator should be designed in order to maximize the dose delivered to 
the tumor and minimize the dose delivered to the rest of the body by varying the diameter, 
thickness, material, and angle of the collimator as shown in Figure 1. 2. The neutron 
Figure 1.2 Collimator Design Parameters 
fluence incident on the collimator is anisotropic and equally distributed across its surface. 
In order to minimize radiation exposure to the body, the neutron leakage from the reactor 
is collimated into a narrow beam. 
In order to maximize the number of patients treated daily and reduce stress on the 
reactor core, the reactor will not shut down between treatments. A shutter should be 
designed to reduce the radiation exposure in the treatment room to levels as low as 
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reasonably achievable, thus allowing unrestricted entry for attending personnel. The 
shutter design should also contain a safety system to insure closure during both normal 
and credible abnonnal operations. 
The overall facility design includes treatment rooms, a confinement building, and 
supporting nledical facilities. The medical facilities will support the outpatient treatment of 
cancer patients in a comfortable environment. The treatment room and confinement 
building will provide protection for the patients, environment, and personnel during 
normal and abnormal operations. Facility economics will also be evaluated for startup, 
maintenance, operating, and decommissioning costs as well as income generated from 
treating patients. 
1.3 Scope and Organization of Work 
Chapter 2 of this report summarizes the history and previous research that has 
gone into making boron neutron capture therapy a viable treatment method. This section 
also summarizes the work that has gone into boron chemistry, animal testing, and clinical 
trials. 
Chapter 3 describes the selection process for finding an appropriate neutron 
source. The advantages and disadvantages of different types of neutron sources are 
discussed. The final selection of the Tower Shielding Reactor is also discussed. 
Chapter 4 summarizes the design of the hydraulics used to move the shutter. 
Safety systems and interchangeable filters are also discussed. 
4 
Chapter 5 summarizes the design of the shutter for the neutron beam. This section 
discusses the materials chosen for the shield. 
Chapter 6 summarizes the design of the collimator for the epithelIDal beam. This 
section also discusses the materials and geometry chosen for the fabrication of the 
collimator. 
Chapter 7 summarizes the design of the facility including the medical, chemical, 
and nuclear aspects. Related equipment required for standard operations and safety are 
also discussed. Additionally, suppliers and cost estimates for the overall facility and related 
equipment are also given in Chapter 7. 
The complete facility design is provided in Chapter 8. A total cost estimate for the 
start-up, maintenance, operating, and decommissioning is discussed. Treatment cost and 
revenue generated are also discussed in Chapter 8. 
Chapter 9 describes work that needs to be considered for the future. 
1.4 Work Breakdown Structure 
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Collimator Design Cases X X X 
Economic Analysis X X 
Economic Research X X X X X X 
Equipment Research X X X X X 
Facility Design X X 
Facility Research X X X X X X 
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Mechanical Design X X X X X 
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2.1 lnitial Clinical Trials15 
The therapeutic potential of boron neutron capture therapy is not a new idea. It 
was a dream first conceptualized in 1936 by G.L. Locher of the Franklin Institute:- but 
was not given form until 1951 by W.H. Sweet. Sweet and his collea!,lUes first 
demonstrated that the chemical compound borax would concentrate in tumor cells in the 
human brain. Shortly thereafter:- clinical trials were initiated at the Brookhaven National 
Laboratory (BNL) in conjunction with the Massachusetts General Hospital. The trials at 
BNL were carried out from 1951 to 1952 and additional trials were carried out from 1961 
to 1962 at the Massachusetts Institute of Technology (MIT). Unfortunately, the trials 
failed to show any therapeutic advantage, and in some cases, actually shortened the 
patient's life. The first boron compounds used did not achieve selective localization in the 
tumor due to their diffusibility and low molecular weight. This, combined with a beam of 
thermal neutrons that was rapidly attenuated in tissue, resulted in massive damage to 
adjacent skin and brain. 
Fortunately, one of the researchers, H. Hatanaka, returned to Japan to continue 
working on boron neutron capture therapy. Dr. Hatanaka treated over a hundred patients 
with a wide variety of tumor grades and history with promising results:- as shown in Figure 
2.1. Group 1 represents 46 patients who received chemotherapy and radiation treatment 
7 
before their BNCT treatment. Group 2 represents all 38 patients that received only BNCT 
between 1968 and 1985. Group 3 represents the twelve BNCT patients with 
tumors less than six centimeters from the surface of the brain. Group 4 represents the 
eleven patients treated between 1987 and 1989. The five year survival rate for Group 3 
patients was 58.3 percent and 68 percent for Group 4. The five year survival rate with 
conventional surgery, chemotherapy, and radiotherapy was 4.6 percent. 
2.2 Boron Chemistry23 
Several nuclides have high cross sections for therrnal neutrons, but boron-lOis the 
only one that is ideally suited for BNCT. Boron-lOis not radioactive and is readily 
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Figure 2. 1 Hatanaka Data 
available, comprising approximately 20 percent of naturally occurring boron. The particles 
8 
emitted by the neutron capture reaction l~(n,afLi have a high Linear Energy Transfer 
(LET), and their path lengths are approximately one cell diameter (10 microns). This 
effect theoretically limits the radiation damage to tumor cells that have taken up a 
sufficient amount of boron-l O. Another advantage of boron-lOis that the alpha particles 
can kill dividing and non dividing cells alike. This is important because tumors are known 
to have a large number of viable but inactive cells, and other fonns of radiation treatment 
and chemotherapy work best only on ceJls that are dividing. 
Boron compounds used in BNCT have a high specificity for malignant cells with 
low concentrations in normal tissue and blood. 10 Initially, boron compounds such as 
sodium borate and boric acid were selected for their availability, known pharmacology, 
and lack of toxicity. The differences in the concentration between the tumor and brain for 
these chemicals, which was small to begin with, dissipated over a period of 1 to 2 hours. 
These shortcomings prompted a major effort in boron chemistry, which resulted in over a 
hundred compounds being screened.6 Eventually, p-carboxybenzeneboronic acid and 
sodium decahydrodecaborate were selected for the first clinical trials at MlT. 
Researchers at Shionogi Research Laboratories developed and synthesized the 
compound Na2B12HllSH, also known as BSH,. for use in BNCT.
18 Dr. Hatanaka 
determined boron uptake by surgically collecting tissue samples from 57 patients. These 
patients received BSH doses of 30 to 80 mg per kilogram of body weight approximately 
twelve hours before neutron irradiation. The average concentration was 26.3 ppm in the 
tumor and 18.2 ppm in the blood, and the mean tumor to blood ratio was 1.69. 
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Recently> there has been an increasing interest in the boron containing amino acid 
boronophenylalanine (BPA).l1 In Japan, BP A was used as a capture agent for BNCT of 
melanomas in both humans and animals?4 BPA has a very low toxicity, a high affinity to 
tumor calls, a tumor-to-blood ratio of3.5, and a tumor-to-brain ratio of3.9. 28 It is these 
characteristics that make clinical BNCT possible. 4 
2.3 Current Clinical Trials25 
Dr. Hatanaka's patients are treated with a thetmal neutron beam that has a 
penetration of 3 to 4 centimeters. In order to treat deep seated tumors, a craniotomy is 
performed to remove the scalp and skull. Even with the craniotomy the treatment lasts 
from 1 to 6 hours. To overcome this limitation, current BNCT research is directed at 
filtering out fast neutrons, thermal neutrons, and photons to produce an epithermal 
neutron beam with an energy range of 0.5 eV to 10 keY. An epithermal neutron beam 
passes through the skin and skull and moderates to thermal energy levels around 2 cm into 
the brain, allowing the treatment of tumors deeper than 4 cm without surgery. With an 
epithermal fluence of lxl09 nfcm2 sec· i , the treatment period is reduced to under one 
hour. 8 
At present, there are two groups in the United States using the epithermal neutron 
beam approach to treat patients on an experimental basis. In 1994 the Brookhaven 
Medical Research Reactor, as shown in Figure 2.2, received approval from the Food and 
Drug Adminjstration (FDA) to treat 28 patients dying of GBM. In 1995 MIT began 
clinical BNCT trials, and the University of Missouri is conducting animal tests?7 It is 
10 
expected that the FDA will give final approval for BNCT to be used as a clinical treatment 
within the next two years. 32 
A - Reactor Core 
B - Beam Shutter 
C - Epithermal Filter 




3.1 Neutron Sources 
An epithennal neutron fluence rate greater than 1 x 109 neutrons cm-2 sec·l is 
needed for successful boron neutron capture therapy. At the present time, only nuclear 
reactors are capable of generating such beams. There are approximately 35 research 
reactors, with power levels greater than 1 MW, in the United States that could potentially 
be modified for boron neutron capture therapy. The Brookhaven Medical Research 
Reactor, the MIT Research Reactor, and the Georgia Institute of Technology Research 
Reactor have irradiation facilities that were designed for medical and biological research. 
One alternative source for the epithermal neutrons needed for boron neutron 
capture therapy is the spontaneously fissioning isotope californium-252. 252Cfhas a half-
life of2.645 years and decays by spontaneous fission 3.09 percent of the time. 252Cfhas a 
prompt neutron emission rate of2.31xlOl2 (neutrons sec-l g-l). The entire supply of 252Cf 
for the western world comes from the High Flux Isotope Reactor (HFIR) at the Oak 
Ridge National Laboratory, which produces less than a gram a year. Over a gram of 252Cf 
is needed to produce an epithermal beam of neutrons of sufficient strength, thus making 
this option economically impossible. 39 
Epithermal neutrons for BNCT can also be produced in low energy proton 
accelerators. The main advantages of accelerator-based designs are a low mean neutron 
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energy from the source~ low gamma ray contamination of the beam, low cost, ease of 
siting in or near hospita1s~ and a compact geometry. A neutron fluence rate of 1 x 109 
neutrons cm-2 sec-l can be obtained from a thick natural lithium target under bombardment 
by a 2.8 MeV proton beam operating at 10 rnA. The high power density deposited in the 
lithium target by a such a beam would melt the lithium metal, even with the most efficient 
of forced water cooling systems. Although liquid lithium targets have been used 
experimentally, having liquid lithium and water in close proximity to the patient's head 
could present a serious problem should one of the cooling lines rupture. Until an advanced 
neutron target is developed, this method is not a feasible neutron source ofBNCT. 
3.2 Possible Reactor Sites in the United States22 
Even if a nuclear reactor has a desirable neutron spectru~ it is usually not feasible 
for BNCT. Most reactors are contained inside pressure vessels surrounded by shielding. 
Some reactors are located in containment buildings or underwater in pools. In order to get 
an epithermal beam of 1 x 109 neutrons cm-2 sec-1 the patient must be located close to the 
reactor, because the fluence rate decreases by approximately {2. For most situations it is 
not possible to place a clinical facility inside a nuclear facility. 
Extensive work has been done on the conceptual design of clinical facilities for 
BNCT at the Power Burst Facility (PBF) at the Idaho National Engineering Laboratory~ 
the Missouri University Research Reactor (MURR), and the Georgia Institute of 
Technology Research Reactor (GTRR). Each of these facilities have outstanding neutron 
beam strength and purity, but each facility has its drawbacks. All three of these facility 
13 
share one common shortcoming: they are research facilities. The GIRR and MURR are 
university reactors that are primarily used for scientific research. If they are used for 
BNCT ~ other research projects will be conducted in the same area. Support facilities will 
be minimal and patients will be under external medical supervision. The PBF could 
function exclusively as a BNCT center~ but at a price. In order to build a treatment roo~ 
a hot-cell needs to be decontaminated and a hole needs to be drilled in the reactor's 
pressure vessel. 13 The estimated cost for the conversion of the PBF is at least 30 million. 
3.3 Possible Reactors Sites at ORNL 22 
Another possible location for a BNCT center is the Oak Ridge National 
Laboratory. ORNL has six potential epithermal neutron sources: the High Flux Isotope 
Reactor, the Oak Ridge Linear Accelerator, the Oak Ridge Research Reactor, the Bulk 
Shielding Reactor, the Health Physics Research Reactor, and the Tower Shielding 
Reactor. Unfortunately~ only one of these reactors can be used for boron neutron capture 
therapy. 
The High Flux Isotope Reactor is a versatile 100 MW reactor that has the highest 
thermal flux (2.5xl01S neutrons cm-2 sec-I) in the world. The HFIR is used for medical and 
industrial isotope productio~ neutron scattering research, materials research, 
transplutonium isotope production, material irradiation, and neutron activation analyses. 
The HFIR currently has three tangential and one centerline beam tube from which to pull 
off neutrons. The best beam for BNCT would come from the centerline tube~ but the flux 
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at the end of the epithermal filter, lxl08 neutrons cm-2 sec-\ would be an order of 
magnitude lower than what is required. 
The Oak Ridge Linear Accelerator (ORELA) has a total neutron production rate 
ofO.8xlOI4 neutrons sec-1 at 50 kW. It has 18 flight stations positioned at 9, 20, 35,40, 
40, and 200 meters from the target. The flux at the closest target, Ixl07 neutrons cm~2 
sec-t, is two orders of magnitude lower than what is needed for BNCT. 1,21 
The Oak Ridge Research Reactor (ORR), the Bulk Shielding Reactor (BSR), and 
the Health Physics Research Reactor (HPRR) have all been shut down. The cost to restart 
one of these facilities and modify it for use in BNCT precludes there use. 
The Tower Shielding Reactor, shown in Figure 3.1, can easily be restarted and 
modified for use in BNCT?O At present, the 1 MW Tower Shielding Reactor (TSR) is 
placed in a concrete shield on an unenclosed 30 meter long by 60 meter wide concrete 
pad. Because there is no building around the reactor, a nuclear and medical facility could 
easily be built on site around the existing structures. This one of a kind spherical core has 
a total neutron leakage of 1.2xl015 neutrons sec-I. By adding a filter, an epithermal beam 
with a fluence rate of over 1 xl 09 neutrons cm-2 sec-I is produced, allowing treatment times 
of less than 30 nunutes. The reactor, location, and facility layout make it ideal for BNCT. 
15 
Figure 3.1 The Tower Shielding Facility 
3.4 The Tower Shielding Facility42 
The Tower Shielding Facility at ORNL was built in 1954 for shielding studies 
needed for the Aircraft Nuclear Propulsion Project (ANP). This research project required 
that the reactor radiation source be located in a region free from ground or structural 
scattering. After the ANP Project was canceled in the early 1960" s, the facility was used to 
conduct a variety of experiments, including Space Nuclear Auxiliary Power, nuclear 
weapons shield studies, civil defense studies, the Liquid Metal Cooled Reactor (LMR) 
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program, the Gas Cooled Fast Reactor (GCFR) program, and for the conduction of large 
scale radiation transport studies. 
The TSF consists of four 96 meter high towers erected on the corners of a 30 
meter wide by 60 meter long rectangle. Two of the towers were originally used for 
suspending the reactor, while the other two were used for supporting other equipment 
such as shield components and detectors. In 1975, the reactor was placed in a ground-
based concrete shield with a horizontal collimator, including a 80 cm diameter stepped 
cylindrical beam port. The shield and collimator were designed to allow placement of 
experimental mockups within 91 cm of the center of the reactor and to provide a relatively 
uniform spatial profile of the neutron source emerging from the beam collimator. 
The reactor collimator opened onto a concrete pad 20 meters wide by 60 meters 
long. The radiation from fission and activation products in the core was attenuated by a 
large movable lead shutter. The shutter was opened only when all personnel were in an 
underground bunker which is covered with 107 cm of dirt and 46 em of concrete. 
The original Tower Shielding Reactor (TSR-I) was a boxed shaped 500 kW 
reactor. It was replaced in 1960 with the spherically symmetric TSR-II, which has been 
operated at power levels of up to 100 kW at both ground level and elevated positions. The 
TSF -II core consists of 60 mm thick curved aluminum-clad uranium-aluminum alloy plates 
cooled and moderated with light water. The plates are shaped so that the assembled core 
is a spherical fuel annulus from which radiation is emitted symmetrically. The neutron-
absorbing control plates for the reactor are contained in the fuel-free region centered 
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inside the fuel annulus. Outside the fuel annulus is a reflector region that can be filled vvith 
aluminum-water, lead-boral-aluminum, or any other combination of material needed. 
3.5 TSR Core Region19 
The fuel annulus, the control ball, and the reflector are contained in the lower 
section of a cylindrical aluminum tank vvith a hemispherical bottom, as shown in Figure 
3.2. This aluminum tank is 244 cm long, has an inside diameter of 94 cm at the 
hemispherical end, and an inside radius of 102 cm at the open end to allow maintenance 
procedures. The core consists of twenty-one fuel elements designed so that the fuel plates 
in adj acent elements join to form many concentric cylinders separated by water passages. 
The spherical annulus is 14 cm thick and has an outside diameter of 74 cm. Each fuel plate 
is 0.15 cm thick and consists of uranium-aluminum alloy clad in aluminum. The fuel plates 
are welded 0.30 cm apart into aluminum side plates to form fuel elements. Three types of 
elements are used: annular elements that form a cylindrical fuel annulus; central elements 
that are used in the upper and lower sections of the core; and one 7.62 cm diameter 
cylindrical plug element, which is centered in the lower central elements. There are 12 
annular elements and 8 central elements in the reactor core. 
The internal reflector region is filled by a 43.18 cm diameter sphere which contains 
six neutron absorbing control plates and the mechanism for positioning them to operate 
and shut down the reactor. The assembled control ball is mounted on four blocks which 
are welded on the inside of the central cylinder. Each control plate is a dished, 
hermetically-sealed hollow plate of 1.59 mm thick stainless steel filled vvith boron carbide. 
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Five shim safety plates move simultaneously relative to the fuel to operate the reactor. 
Each plate is independently driven toward the fuel, four outward and one downward, to 
shut down the reactor. The sixth regulating plate moves vertically in the upper region of 
the sphere and can be servo-operated to maintain the reactor power at a constant level. All 
cavities within the control ball are filled with water. Movement of the control plates is 
achieved by a combination of mechanical and hydraulic forces. As the control plates are 
pushed away from the fuel, a shutdown spring is loaded. In the case of an emergency 
shutdown, the shutdown spring will fully extend the control plates. 
3.6 Core Heat Transfer 19 
The reactor was designed so that the surface temperature of the fuel plates is 
maintained below the saturation temperature of water at every point in the core. The 
saturation temperature in the core is 139.4 C at a pressure of 0.251 .MPa. Under normal 
operating conditions, the cooling water flow rate is approximately three m3 min-} and the 
maximum allowable power is 1 MW. If the power level were raised to 3 MW and the 
cooling water flow rate was dropped to 1.5 m3 min-}, the maximum fuel temperature 
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Figure 3.2 TSR Pressure Vessel 
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3.7 Site Location and Regional Support42 
The Tower Shielding Facility is located approximately 9 miles from the city of Oak 
Ridge~ Tennessee and 21 miles from the city ofKnoxville, Tennessee. The site is located 
on the edge of ORNL and is easily accessible from Interstate-40. The TSF is easily 
accessible for the Southern, Northeastern, and Midwestern States. 
Besides ORNL, a BNCT facility at the Tower Shielding Facility has enonnous 
regional support. The Tennessee Center for Research and Development (TCRD) has 
shown an consistent interest in developing a clinical facility. Due to TCRD's efforts~ the 
Department of Energy (DOE) has agreed to lease the TSF for up 99 years to interested 
parties. 
The University of Tennessee, Knoxville can support all aspects ofBNCT 
development and Treatment. Dr. George Kabalka from the Department of Chemistry is 
one of the countries leading authorities on boron chemistry and is currently active in the 
development of BP A and other advanced boron compounds. The University of Tennessee 
Medical Center and Cancer Clinic can provide medical therapies~ radiological oncology~ 
surgical procedures~ pharmacological research, and patient diagnosis. The University of 
Tennessee also has one of two magnetic resonance imagining (MRI) machines in the 
country capable of imaging boron instead of hydrogen. Additional support can be 
provided by the Department of Veterinary Medicine for animal testing and by the 
Department of Nuclear Engineering for nuclear research. 
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Chapter 4 
Beam Shutter Mechanism 
In order to maximize the epithermal fluence rate to the patient during treatment, 
and minimize the total dose rate between treatments, a shutter mechanism is needed to 
turn the beam on and off The shutter mechanism has passive safety features and the 
capability to interchange beam filters. The main limitations imposed on this design are the 
allowable dimensions, safety, availability of equipment, and cost of equipment. 
4.1 Description of System and Operation 
In previous experiments at the Tower Shielding Reactor the Large Concrete Beam 
Collimator (LCBC) acted as a horizontal shutter and collimator as shown in Figure 4.1.42 
Although the LCBC attenuates decay radiation from fission products and activated 
materials, it does very little when the beam is activated. By removing the LCBC, patients 
can be positioned 38.73 cm closer to the core of the reactor, producing a fluence rate 








Figure 4.1 Existing Collimator/Shutter Confi~'1Iration 
In order to keep the patient as close to the reactor as possible, the shutter and filter 
should be attached and move together. Because the distance to the patient must be 
minimized, the shutter/filter assembly can only move horizontally or vertically, as shown in 
Figure 4.2. The horizontal configuration allows easy overhead access to both the shutter 
Horizontal i 
Vertical 
Figure 4. 2 Shutter/Collimator Movement 
23 
.. 
and the filter, but it is difficult to move. In the vertical configuration it is difficult to 
change the beam filter, but the system has gravity as an inherent safety feature. 
Figure 4.3 Shutter in the closed position 
In order to get a fast, effective, and safe shutter/filter syste~ the best option is the 
vertical configuration hydraulically lifted with the shutter stacked atop the filter. The 
assembly would remain in the lowered position with the shutter in front of the reactor 
beam portal until the time for therapy to begin, as shown in Figure 4.3. At the beginning of 
the therapy the hydraulic system will activate and the filter and collimator will be lifted 
into the position between the reactor beam portal and the patient, as shown in Figure 4.4. 
At the end of the treatment session the hydraulics win lower and the shutter will again 
cover the beam portal, making the treatment room safe for facility workers to enter while 




Figure4.4 Open shutter configuration 
4.2 Interchangeable Filter Design 
In order to maximize revenues, the BNCT Tower Shielding Facility can also treat 
melanoma, lung, colon, prostate;. and breast cancer. Each type of cancer requires a unique 
filter and collimator, and this design has the capability to change the filter/collimator 
assembly with ease. A cross bar installed at the shutter rest position is capable of holding 
the shutter section of the assembly in place without the spectrum modifier in position. This 
allows the further lowering of the filter/collimator assembly clear of the cross bars. At this 
level the filter/collimator can be removed from either side and replaced with a different 
type of spectrum modifier and collimator. 
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4.3 Safety Features 
The primary concern in this design choice is safety. This design employs an innate 
gravity safety feature; in the event of an accident where the hydraulics would fail, the 
assembly will fall into the closed position and end any radiation exposure to the patient. 
The shutter section of the assembly has been designed to be 50 cm wider than the 
spectrum modifier section of the assembly. Within this additional space there will be two 
dual purpose cross bars located at the base of the shutter when it is in the lowered 
position. These bars would provide a resting place and emergency support for the shutter 
should there be any reason that the spectrum modifier or hydraulics failed to support it. A 
series of guide bars are also placed along the side edges of the walls, beginning at the 
cross bar and extending to the top of the shutter in the raised position. These are to insure 
that the assembly does not move from its intended vertical course and that it cannot be 
inadvertently or accidentally removed from the beam portal opening. An additional 
hydraulic power unit, reservoir, and pump are included in the confinement building for 
system redundancy. 
4.4 Hydraulic System Specifics 7 
The hydraulic lifting system for the filter/collimator assembly, shown in Figure 4.5, 
is required to raise approximately 11,000 kg 2.5 meters. For safety and future 
expand ability of the facility, the lifted mass was rounded up to 18,000 kg. This height was 
determined from the maximum distance that the assembly will need to be raised plus an 
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additional amount for changing the filters. A vertical lifting force twice the weight of the 
Shutter 
Filter 
Figure 4.5 Hydraulic System 
obj ect being lifted is needed for fast operation. The hydraulic system required for this 
application consists of four separate five inch bore cylinders, each with a two inch 
diameter rod., capable of lifting over 37,000 kg. A cylinder is placed at each comer of a 
] 10 cm wide by 72 em long plenum on which the filter and shutter will rest. For added 
safety, an additional cylinder of identical dimensions is located at the center of the plenum 
so in the event that one of the exterior cylinders should fail, the assembly can be safely 
guided to the closed position. Each of the cylinders operate at 8.69 MPa delivering over 
9,350 kg of force, which will more than adequately cover any future need of the facility. 
The cylinders can be obtained at an estimated cost of approximately $4,870 each. In 
27 
addition to the cylinders, a hydraulic power unit with a 114 liter reservoir and pump will 
be required. The estimated cost for the pump and reservoir is $3,500, and the 




The beginning of the shutter assembly is located 53.66 cm from the center of the 
reactor. The combined neutron and gamma dose rate at this point is approximately 3 x I 05 
Sv hOU{l. The recommended annual limit for radiation workers is 50 mSv yr-l.38 In order 
to reduce the dose rate to acceptable levels, a shutter 110 cm thick must be constructed to 
attenuate the beam. The shutter must protect both the patient and the facility staff from 
unnecessary radiation exposures. The primary limitations imposed on the design are the 
allowable dimensions, mass, safety limits, cost, and feasibility of manufacture. 
5.1 Shutter Calculations44 
The shutter calculations were performed using XSDRNPM (X-Section Dynamics 
for Reactor Nucleonics with Petrie Modifications) running on a Sun SP ARC server lOOOE 
with a 84 group P 5 cross-sections library and external source provided by ORNL. A 
program, called DOSE, was written to easily display the :fluence and dose rates at the last 
spatial mesh point.33 
29 
5.2 Detailed Description of Shutter Design 
In order to maximize the number of patients treated per day and to minimize 
operational stress on the reactor and control ball, the facility will operate at during 
treatment and 100 kW between treatments. A beam shutter is used to reduce the radiation 
levels in the treatment room to as low as reasonably achievable when the reactor is 
operated at 100 k W. 
Approximately 84 different shielding models of varying thickness and composition 
were considered. Water and concrete are poor shields for this application, as shown in 
Table 5.1. The water shield thermalizes neutrons, but allows a large number of gamma 
rays to pass through uncollided. The concrete shield blocks the gamma rays, but allows 
the fast neutrons to pass through. A mixture of borated polyethylene and tungsten provide 
the best shield for the limited space. The borated polyethylene has a high hydrogen 
content, allowing it to thermalize the fast neutrons, while the tungsten provides gamma ray 
shielding. 
Table 5.1 Shutter Calculations 
Shielding Configuration Dose (Sv/hr) 
110cm Water 176 
110em High Density Concrete (HD) 6.64 
aDem HD, 20cm Water, 1cm Cd, gem Pb 1.71 E-02 
1 Oem W, 72cm B-Poly, 18cm B\, 1 Oem Li-Poly B.16E-03 
15em Bi, 68em B-Poly, 13cm W, 14em B-Poly 3.68E-03 
1 Oem W, 15cm B-Poly, 5em W, 50cm B-Poly, 1 Oem W, 1.70E-03 
20em B-Poly 
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The final shutter design, shown in Figure 5. 1, reduces the dose rate at 1 MW 
operating power to 1. 70x] 0-3 Sv hr-] on the wan closest to the reactor. When the reactor 
power is lowered to ]00 kW, the dose rate drops to 1.07xlO-5 Sv hr-1, which is an 
acceptable limit with an occupancy factor of 4 hours per week 
Tungsten 
B-Poly 




The major criterion that one must consider when designing a collimator for use in 
boron neutron capture therapy is to deliver the highest possible thermal fluence to the 
brain, while administering the lowest achievable whole body dose. The spectrum of the 
beam is modified to the optimal spectrum for boron neutron capture therapy by a filter 
designed by engineers at ORNL. Other limitations imposed on the design the allowable 
dimensions, mass, safety limits, cost, and feasibility of manufacture. 
6.1 Collimator Modeling and Calculations 43 
The two dimensional discrete ordinance program DORT is ideally suited for 
collimator and shielding design because it generates the exact fluence rate for each mesh 
point. An 84 group cross sections with P j scattering and a combined gamma ray and 
neutron source were provided by ORNL. All DORT calculations are performed on four 
Sun SPARCstation 20's, one SPARCserver 690, and one SPARCserver 1000E using Ps 
scattering, a S-16 quadrature, 84 group cross sections, and the supplied reactor source. 
Although most calculations were finished in under an hour, DOR T requires a large amount 
of disk space to store the output files and special programs to read them~ 
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6.2 Programs to Analyze DORT Outpue3,29 
Two programs were written to analyze the flux output from DOR T. The first 
program, called FLIP (Elux Linear Interpolation :erogram), takes the boundary source 
provided by ORNL 26 and interpolates it to the intervals needed for the collimator 
geometry. This is necessary because ORNL's filter model has different intervals than 
what is needed for the design of the collimator. FLIP reads the intervals from an input file 
called READFLUX.INP, which contains ORNL's original intervals and the new 
collimator intervals. 
The second program, called DRIP (DORT Reading Interpolation ~rogram), reads 
the flux output from DORT. DRIP displays the fluence and dose rate for each energy 
group at points specified in an input file. The dose rate is calculated by multiplying the 
energy dependent 1991 ANSI standard dose response function, VELM61.DRF, by each 
energy group. The fluence and dose rates are displayed in a table and a Postscript flux 
map of the output is displayed. 
A test was performed before running any calculations to verifY that the source 
created with FLIP was the same as ORNL's. The fluence rate calculated with the modified 
source was compared to a sample problem supplied by ORNL at two points: 0,0 and 50,0. 
Both points were in close agreement, as shown in Figure 6.1 and 6.2. 
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Figure 6.2 Verification of Source at Point (50, 0) 
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6.3 Collimator Optimization 41 
Three points of interest are used to determine the optimal col1imator design. The 
first point is along the centerline of the reactor at the col1imator exit where the epithermal 
neutron fluence should be the highest. The second point is 7 cm into the brain9 where a 
high thermal fluence is needed. The third point is 50 cm to the right of the center of the 
bra.in where the total fluence rate should be low. This point is of importance because 
limiting the whole body dose is a major design restriction. 
The first mesh used to model the filter and coHimator consisted of approximately 
13,000 one cm by one cm mesh points. In order to cut down the CPU time for each 
calculation, a course mesh of approximately 5,700 points was used instead of the fine 
mesh. A comparison of the fine mesh to the course mesh at the collimator exit is shown in 
Figure 6.3, and for 7 cm into the brain in Figure 6.4. Because the flux distributions are 
similar, the course mesh can be used to reduce runtime from 8 hours to under one hour. 
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7 em Into the Brain 
In collimator design five properties are varied in order to achieve the optimal 
thermal neutron fluence and penetration into the brain. These properties include the 
collimator material, the radius of the opening, the angle of the collimator, the thickness of 
the collimator, and the overall position of the collimator, as shown in Figure 1.2 (page 
3). Eighty-nine different collimator models were created and analyzed by varying these 
parameters. 
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Materials used in a collimator should rapidly moderate~ absorb, and/or scatter 
neutrons so that the majority of neutrons reaching the patient are coming through the 
collimator opening. Lithiated polyethylene, lithiated paraffin, and borated polyethylene are 
good moderators because of their high hydrogen content. Lithium and boron have high 
absorption cross sections for thermal neutrons and decay by alpha emission. Out of five 
collimators made of Iithiated polyethylene~ lithiated paraffi~ borated polyethylene, 
concrete, and aluminum, the lithiated polyethylene and aluminum collimators have the 
highest epithermal fluence rates. A comparison of the models at the collimator exit shows 
that the aluminum has a clear advantage over the lithiated polyethylene~ as shown in 
Figure 6.5. A comparison of the two models seven cm into the brain shows that the 
aluminum has approximately two times the fluence rate of the lithiated polyethylene, as 
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Figure 6.5 Material Changes at Collimator Exit 
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shown in Figure 6.6. Unfortunately, aluminum has a high epithermal and thermal fluence 
rate because it is a poor collimator. The neutrons that pass through the aluminum lose 
very little energy when compared to the lithiated polyethylene, as shown in Figure 6.7. In 
order to nunimize the dose to the patient's body and maximize the epithermal fluence, 
lithiated polyethylene is used as the collimator material. 
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The radius of the collimator opening determines the size of the epithermal beam 
used during treatment. For the treatment of deep seated brain tumors, like GBM, a wide 
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collimated epithermal beam works better than a narrow col1imated beam . Two models 
with a 6 cm and 9 cm radius are compared at the collimator exit in Figure 6.8. In order to 
maximize penetration, as shown in Figure 6.9 by the higher fluence rate~ a 9 cm radius is 
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By decreasing the angJe of the collimator, the attenuation provided by the lithia ted 
polyethylene is reduced. Although this allows more epithermal neutrons to pass 
uncollided, there is an associated increase in fast neutrons and gamma rays, as shown in 
Figure 6.10. The negative effects of the fast neutrons and gamma rays is outweighed by 
the positive effects from increased penetration provided by the eleven degree collimator~ 
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Figure 6.10 Changes in Angles at the Collimator Exit 
~;:- 1.50E+08 -r---------------rr .... 
CD < 
..J en 1.00E+08 
::~ 
c < 
:::l E 5.00E+07 
i (J 
0.. 
>< .:.. O. OOE +00 H+I·-++f+!+H++++"I"+"H+H~t+H+H++++++_fo+~I#+II=~+H+i 
:::s -c- ro L() N m <0 (1') 0 ~ u: -c- N N (1') ~ ~ ~ 
Energy Group 




----- 90 Degrees 
--11 Degrees 
--45 Degrees 
---- ro Degrees 
Varying the thickness of the collimator has approximately the same effect as 
changing the collimator angle. By decreasing the thickness, more epithermal neutrons can 
pass through the collimator uncollided, as shown in Figure 6.12. Changing the thickness 
of the collimator does not drastical1y change the penetration. The real disadvantage of thin 
collimators is that they provide little protection to the patient's body, as shown in Figure 
6.13. For this reason, a 10 cm thick collimator is used to reduce beam contaminates 
produced from lowering the collimator angle. 
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Figure 6.12 Thickness Changes at the Collimator Exit 
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Figure 6.13 Thickness Changes 50 em to the Right of the Brain 
The overall positioning of the collimator with respect to the last layer of bismuth 
in the filter was examined. By placing the collimator inside the bismuth layer, the air gap is 
removed and the patient is moved closer to the reactor. A model with the coJlimator 
placed entirely in the bismuth layer with no air gap, a model with 5 cm of the collimator 
placed in the bismuth, and a model with the collimator in the normal position are 
compared. Even with the patient closer to the reactor, the standard collimator has a higher 
epithermal fluence rate at the collimator exit, as shown in Figure 6.14. Placing the 
collimator inside the bismuth not only lowers penetration but increases the gamma ray 
dose delivered to the patient's body, as shown in Figure 6.15. The geometry that 
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Figure 6.15 Position Changes 50cm to 1he Right of the Brain 
6.4 Detailed Collimator Design 
In order to decrease the amount of filter material used and increase the epithermal 
fluence rate at the collimator exit, the filter/collimator assembly is cylindrically shaped, 
wrapped in a reflector, and fits directly over the reactor beam port. Beryllium, lead, 
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tungsten, aluminum, and graphite were tested as reflectors. The test results are as shown 
in Table 6.1. 








In order to maximize the epithermal fluence rate~ lead is used as the reflector even though 
it also increases the fast neutron fluence rate. 
The final design is a 10 em thick lithiated polyethylene collimator with a 9cm 
radius and an 11 degree angle. The collimator is attached to the filter and wrapped in lead 
as shown in FibJUre 6.16. The total neutron and gamma ray fluence rate across the outside 
surface of the final collimator is shown in Figure 6.17. The fluence rate decreases at an 
acceptable rate across the collimator~ but some neutron Jeakage is still coming from the 
reflector and air gap. The thennal and epithermal neutron fluence from the exit of the 
collimator and through the phantom is shown in Figure 6.18. The thermal fluence rate 
peaks at approximately three centimeters into the brain, approximately five centimeters 
from the collimator, and then slowly decreases. With this thennal distribution, any tumor 
located in the head can be treated. 
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Figure 6.18 Thermal and Epithennal Penetration into the Brain 
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Chapter 7 
Clinical Facility Design 
7.1 Site Location42 
The Tower Shielding Facility is located on a hin with an elevation of 1069 ft 2.35 
miles south-southeast of Oak Ridge National Laboratory (ORNL). It is 9 miles from the 
city of Oak Ridge, Tennessee and 21 miles from the city of Knoxville, Tennessee. The 
immediate terrain on all sides of the tower structure slopes downward at the base of the 
towers, and the grade gradually rises to the top of Copper Ridge, approximately 400 ft to 
the north of the towers. 
7.2 Present Tower and Facility Layout42 
Since the TSR-It is currently classified as an unshielded reactor, the TSF is 
situated within a general exclusion area that is enclosed by a 6-ft-high chain-link fence 
topped with three strands of barbed wire. 
Two reinforced-concrete underground buildings are located adjacent to and north 
of the towers, as shown in Figure 7. 1. The smaller building is used as a service and shop 
area and is connected to the larger building by an 2.44 meter wide walkway. The larger 
building contains the reactor controls, data-collecting facility, counting room, and offices. 
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The buildings are shielded against radiation by an 0.46 meter thick concrete roof covered 
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Figure 7.1. U odergrouod Bunker 
The tower structure is a braced and guyed steel frame forming a 30 meter by 61 
meter rectangle> with a leg placed at each of the four comers. Each leg is 2.75 meters 
square, 96 meters high, and terminates at the lower end in an inverted truncated pyramid. 
Each pair of legs is joined at the top by a horizontal truss-type bridge running east and 
west. Maintenance access is provided by a bridge between legs I and IV of the north 
tower. 
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The tower structure is protected from lightning by means of a wire grounding net. 
A copper-clad steel-strand shielding wire is mounted on porcelain insulators to form a 
rectangle at a 5-ft minimum above the entire structure. Shielding wire also extends from 
the top of each tower to the ground to protect the inclined guys. The steel towers, the 
inclined guy wires, and the grounding system are connected to a buried counterpoise. The 
resistance to the ground of the above-ground grid system is between 1 and 3 ohms. 
A two-section reinforced concrete pool provides shielding during the removal and 
storage of fuel elements. The pool is located midway between the west tower legs; its 
large section is 6.10 meters square and 7.62 meters deep. The small section of the pool is 
1.22 meters wide, 3.66 meters long, and 6.71 meters deep. A guided float is installed in 
the pool for raising and lowering reactor shields. The water in the pool is circulated 
through a system of filters to keep it clear for raising the shields. 
7.3 Proposed Additions 
An outpatient medical facility, estimated to cost between 1.8 and 2 million dollars, 
will be constructed at the reactor site to house the necessary equipment for the boron 
neutron capture therapy, as shown in Figures 7.2 and 7.3. 
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Figure 7.3. O,'emead View of Facility 
A confinement building, 30.48 meters long and 15.24 meters wide, with 0.45 meter 
thick concrete walls, is added around the reactor and pool to insure that exposure is 
limited to very low doses and all radioactivity is contained. A 9.14 meter long and 4.57 
meter wide loading area is located in the northwest corner of the confinement building. 
The treatment room is 15.24 meters wide and 15.24 meters long to reduce neutron 
backscatter. It is located immediately adjacent to the east side of the reactor, adjoining the 
confinement building at the reactor porthole. The treatment room will have 0.45 meter 
thick concrete walls with IS cm borated polyethylene tiles to absorb any backscatter 
radiation from the neutron beam. The dose rates outside of treatment room are shown in 
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Figure 7.4. On the south side of the treatment room wiH be an observation room, 6.10 
meters long and 3.66 meters wide, that will allow medical personnel and the patient's 
family to observe the treatment. 
8* 10-6Sv/hr 
t 
Figure 7.4 Doses Outside Treatment Room 
3*10-6 Sv/hr 
4*10-6 Sv/hr 
7* 10-7 Sv/hr 
Should an emergency in the treatment procedure arise, an emergency room, 6.10 
meters long and 7.62 meters wide, will be located on the south side of the treatment room 
so that the patient may be taken directly from the treatment room to the emergency room. 
The primary emergency room equipment can be purchased for approximately $30,000. If 
a medical enlergency occurs while the patient is in the treatment room, a surgical scrub 
room, 3.04 meters wide and 3.04 meters long, will be accessible to the emergency room 
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so that physicians may properly prepare for surgery. The cost estimates for the surgical 
scrub room equipment are $]0,000. 
A maintenance room, with dimensions of 6.10 meters long and 6.10 nleters wide, 
will be added for eJectricaJ and mechanical support. The facility has two storage areas: one 
on the north side of the treatment room, connected to the maintenance room, and the 
other adjacent to the observation room on the south side of the treatment room. A faculty 
lounge, 6.10 meters long and 3.51 meters wide, is located north of the maintenance room. 
Six offices for physicians and technicians will be in the northwest comer of the facility, 
along with a conference room. 23 
7.4 Optional Thermal Treatment Room 
An additional treatment room can be added into the existing facility with minor 
modifications to reactor and shutter assembly. Neutron leakage from the primary filter is 
directed through a tank of heavy water, which moderates the fast and epithermal neutrons. 
With 30 cm of heavy water place 97 cm from the beam centerline, as shown in Figure 7.5. 












Figure 7.5 SL"Condary Treatment Room 
7.5 Treatment Sequence 
Upon arrival at the facility, the patient and his or her family enters a 12.34 meter 
long by 6.25 meter wide waiting room at the main entrance on the west side of the 
building. The patient then registers at the reception area. Restrooms are accessible from 
the waiting room adjacent to the reception area. The physician then directs the patient and 
family from the waiting room to an exam room. There are eight examination rooms;> 3.05 
meters wide and 6.10 meters long, located south of the emergency room. Each 
examination room is estimated to cost $9;>000. The total price for all examination rooms is 
approximately $80,000, which includes a nurse call system. A technician or nurse 
prepares the patient for treatment, and takes any final measurements for dose calculations. 
These calculations are determined on computers, estimated at $70,000 each, which are 
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housed in the pretreatment planning room located on the southeast comer of the facility. 
A chemistry laboratory, 6.10 meters square, and a pharmaceutical laboratory, 6.10 meters 
long and 3.66 meters wide,. is located west of the examination rooms and are used to 
quickly transfer and administer the boron pharmaceutical to the patient. After the patient 
has received the boron compound, he or she is transferred to the treatment room. The 
. family can then move to the observation room or back to the waiting room. After the 
treatment has been completed, the patient is returned to the examination room for post-
treatment observation. 
7.6 Filtration System45 
The confinement building and the treatment room have separate air filtering and 
ventilation systems from the rest of the facility to contain radioactive particles in the event 
of an emergency. To maintain the facility the two rooms have individual vacuum control 
systems but can share a common filtration system. Each of the vacuum control systems 
include two redundant fans, a differential pressure sensor, motor operated dampers, and 
control circuitry. Due to the need to combine the ductwork to the filtering system, the 
treatment room is kept at a higher pressure. If there are any leaks, or if the system should 
fail, the net leakage of material is directed into the confinement building and not the 
treatment room. The air filtration system for the confinement building and the treatment 
room consists of a filter unit, a centrifugal fan, and an air flow control module. The filter 
unit contains a demister, a relative humidity heater, a prefilter bank, HEPA filter bank, two 
banks of carbon absorbers in series, and another HEP A filter bank. The air flow control 
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unit contains a differential pressure sensor and transmitter, control circuitry, a damper 
actuator and two modulating dampers. The vents from this system are equipped with 
radiation monitoring equipment. This system creates the need to limit the recirculation of 
the air to the confinement building. The monitored vents in the treatment room can also 
act a removal system in case of an accident involving leakage of material into the 
treatment room and additional facility areas. This system is the mirror image of the type 
currently used in power producing nuclear plants, and is more than adequate to meet 
requirements. 
7.7 Reactor Coolant System35,42 
The existing reactor coolant system consists of a main pump that pumps 
demineralized water from the detention tank through an aluminum pipe into the reactor. 
The hot leg coming out of the reactor then goes to forced draft air radiator. In order to 
obtain a Class 104 license from the Nuclear Regulatory Commission, this system needs a 
substantial upgrade. 
A flow header is placed on top the pressure vessel to provide three separate 
coolant loops. Each coolant loop has its own heat exchanger, with 5 m2 of surface area, 
and a 7,500 W pumping system. Each added loop costs approximately $20,000. The 
forced air radiator is replaced with a cooling tower approximately 6 meters wide, 12 
meters long, and 6 meters high at a cost of $20,000. 
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7.8 Future Expansion 
The proposed facility is designed for outpatient treatment in order to minimize 
startup cost. The facility also has the capability to be expanded for additional inpatient 
accommodations when more revenue is desired. Long term patient rooms::> a cafeteri~ an 
X -ray room, an MRI room, a PET scan room, and additional office space ·can be added on 
the ground level as well as second and third floors. A research laboratory and facility for 
animal testing has also been proposed for research on other treatments::> such as those for 
lung, breast::> colon, and prostrate cancer. This facility would be in a separate building 
from the treatment center, so that sanitation could be assured for patients. Table 1 




In conclusion, the optimally designed collimator yields an epithermal neutron flux 
of3.44x 109 neutrons cm-2 see-} at the eollinlator exit, and a thermal neutron flux of 
] .58x109 neutrons em -2 see·l at a point 1 cm into the brain. Thus, the 1 MW reactor at 
the Tower Shielding Facility can be utilized to generate a more optimal does than that 
currently being used at the 5 MW reactor at Brookhaven National Laboratory. 
(Epithermal neutron flux of 1.8x109 neutrons cm-2 sec· i ) 
The conceptually designed shutter lowers the dose to 1.1x 1 0-3 Sv hr-I at the 
shutter's surface when the reactor is operating at full power. 
The overall facility conceptual design incorporates all the necessary medical 
accommodations in an efficient, outpatient clinic. The treatment room is designed with 
0.46 m thick concrete walls with a layer of 15.2 cm of borated polyethylene to minimize 
both the dose to adjacent rooms and the backscatter dose to the patient. 
The entire conversion process and construction of the facility would cost 
approximately $20 million, and could generate approximately $24 million in annual 




There are several design considerations that have not been mentioned thus far. 
These will need to be addressed in order for the conceptual design of the BNCT clinical 
facility at the Tower Shielding Reactor Site to be complete. 
A feasibility study for a third treatment room with major structural changes will 
need to be made. Also, the a feasibility study of converting the facility from an out patient 
facility to a primary care facility that is self-sufficient needs to be performed. The current 
facility design must include paving and additional parking with an economic analysis of 
the two. A conceptual development of the second treatment room with a maximized beam 
must also be developed. 
In the future, one must evaluate the currents, neutron kerma, and kerma at the 
collimator exit to generate an intensity vs. purity plot for comparison with ORNL' s 
optimum beam. 
For the optimum beam and a minimized dose at the shutter exit, codes must 
continued to be run. A detailed analysis of the thermal hydraulics must be performed. 








character* 120 aline,aprev 
print*,' XSDRNPM output file?' 
read(*, '(a20Y)xsname 




C print *,aline 
C 
C***************************************************************** 
10 if(aline(3: 12).ne.'total flux')tben 





print * ,aline 
C***************************************************************** 
go to 10 
endif 
read( 1, '(aI20)')aline 
read( 1, '(a 1 20)')aline 
do 30 ibase=O,9 
20 if(aline(3 :6).ne.'int.')then 
aprev=aline 





print * ,aline 
C***************************************************************** 
go to 20 
endif 
read(aprev, '(7~8n3.0)')(flux(ibase*8+i),i= 1,8) 
read( 1, '(a120)')aline 
30 continue 

















print * ,aline 
C***************************************************************** 
go to 40 
endif 
read(aprev, '(7x,8fl3.0)')(flux(i),i=81 ,84) 
call daiso('velm61.drr,l, 1 0000) 
call daisr('drf,0,84,drf,l) 
vai=O. 





*'======= ============ ===','=========== ==:=========:=') 
9020 format(4x,i4,2x,lpe12.5,1x,lpeI4.7,Ix,OpnO.4) 











parameter(nscrx= I 0000) 
parameter(ncscrx= I 0000) 
character* 1 zca 
commonlscrchlnscr ,za( nscrx),izzz 1 ,izzzm 
commonlcscrchlncscr ,zca( ncscfx),izzzcm 
ratio 1 =(izzzm * 1. )/(nscrx* 1.)* I 00. 
rati02=(izzzcm*1.)/(ncscrx* 1.)*100. 
write(*,9010)izzzm,nscrx,ratiol 
9010 format(/l7h EXT used ,ilO,8h out of ,ilO, 
*25h reallintegervariables (,:f8.3,2h%» 
write(* ,9020)izzzcm,ncscrx,rati02 




subroutine daiso(a200,lu,idum) 02/19/94 
C********************************************************************** 
C 
C Module name: 
C DAISO 
C 
C Called modules: 
C GTTOKE 
C 





C A20 C*( 
C LU 1*4 
C 
C Internal variables: 
C ALINE C*80 
C 
C Variables read: 




character* 32 token 
integer*4 toklen 





data lusll ,9 1,92,93,94,95,96,97,98,99/ 
lus(l)=lu 











if(aline(l :8).eq.'include ')then 
do il=9,38 









40 ifile=ifile+ 1 
if(ifile.gt.l0)then 
write(* ,901 0)a30,afilc(ifile-l) 
9010 format(/2x, '======================', '========================', 
*'========'/2x, '=',54x:='l2x, '=',5x, 'DAISY input error!.,3lx,'='1 
*2x,'=',54x,'='/2x,'=',5x,'The include of file ',a28,lx,'='/2x, 
*'=',5x, 'by file ',a28,13x:='/2x,'=',54x,'='/2x,'=',5x, 
*'Exceeds the limit of 10 ','nested includes', lOx, '='/2x, 1=' ,54x, 
*'='/2x,'=',5x,'Halting execution.',31x,'='/2x,'=',54x,'='/2x, 





do j= I, ifile-l 
if(afile(ifilc).eq.afile(j»tben 
write(* .9020)afile(ifile-1 ),afile(j) 
9020 fOl1IIat(/2x, '=======================' ,1======================1, 
*'========'/2x,'=',54x,'='/2x,'=',5x,'DAISY input error!',3Ix,I='1 
*2x,'=',54x,'='/2x,'=',5x, 'File ==> ',a28, 12x,'='/2x,'=' ,5x, 
*'includes file ',a28,7x,'='/2x,'="54x,'='I2x,'=',5x, 
*'whlch is already open' 27y '='/2x '=' 54 y '='/2x '=' 5x, 
.. , &'") "..., " 









go to 20 
50 close(lus(ifile» 
ifile=ifile-l 





C TemJX)rary write 
C 
C********************************************************************** 
C write(* ,9030)ntoke 
C 9030 formate ntoke ',i5) 
C '\\'fite(* ,9040) (i, token(i),i= I ,ntoke) 
C 9040 format(5x,i5,a) 
return 
end 
subroutine daisr(atitle,idfalt,nvald, val,ist) 
C********************************************************************** 
C 
C Module name: 
C DAISR 
C 
C Called modules: 
C DAISF 
C 





C External variables - used: 
C ATITLE C*( 
C IDFALT 1*4 
63 
C NTOKE 1*4 
C NVALD 1*4 
C TOKEN (ntokex) C*32 
C TOKLEN (ntokex) 1*4 
C VAL (*) C*( 
C 
C External variables - set: 
C TOKEN (ntokex) 
C VAL (*) 
C 
C IntemaJ variables: 
C IT 
C 
C Variables read: 
C VAL (*) 
C 
C Variables written: 
C ATI1LE 
C NVALD 











character* 32 token 
integer*4toklen 
















9010 format{II' DAISRERROR- VARIABLE ',a32,' NOT FOUND') 
write(* ,'(//)') 















if(idfalt. eq. 0) then 
wrile(* ,9020)atille,nval,nval~(ii,val(ii),ii= l,nval) 
write(* :(/1)') 
write(99, 9020)atitle,nval,nvald,(ii, val(ii),ii= 1 ,nval) 
write(99,'(/I)') 
9020 formate//' DAISR ERROR - ARRAY ',a32f is only given " 






















C Special symbol = r 
C c nrep val repeats value VAL NREP times 
C 
C********************************************************************** 








read(token (it), 9040)rep 
do i=l,nrep 
nval=nval+ 1 





C Special symbol = f 
65 
C f val fills rest of field with value VAL 
C 
C********************************************************************** 
elseif(token(it)(] : 1 ).eq. 'f) then 














C Special symbol = e 
C e Does nol bother rest offield (Allows progrdIIlmer to 
C initialize input values to defaults) 
C 
C********************************************************************** 





C Special symbol i 
C vall i nint val2 = Interpolates NINT values between VALl 
C and VAL2 (results in NINT+2 entries) 
C 
C********************************************************************** 












val( nvaI)=vall +( val2 -vall )* i/( nint + 1.0) 
enddo 
mlal=nval+ I 




C Special symbol 1 
66 
C val I I nint vall Interpolates NINT values between VALl 
C and VAL2 (results in NINT+2 entries) 
C 
C********************************************************************** 





vall =val( nval) 
do i=l,nint 
nval=nval+ I 
c val(nval)=vall +( val2-vall )*iI(nint+ 1.0) 







C Special symbol = m 
C m niDt vall 'val2 = Delivers the midpoints of NINT regions 




elseif(token(it)(I: I ).eq.'ml)then 
if(10klen(it).cq.1 ) then 
it=it+1 
clse 






































e External variables - used: 
e ATITLE C*( 
e 1ST 1*4 
e NTOKE 1*4 
e TOKEN (ntokex) e*32 
e 
C External variables - set: 
e IT 1*4 
e 
C********************************************************************** 
panuneter(ntokex= 1 00000) 
character*32 token 
integer*4 toklen 
commonltokenlntoke, token(ntokex), toklen(ntokex), irefind 
panuneter(nequalx=3000) 
character*( *)atitle 












do ie= l,nequal 




10 do j=ie,nequal 
i=iequals(j) 











subroutine gttoke(atine) gttoke 1 
C********************************************************************** 
C 
C Module name: 
C GTTOKE 
C 
C Called by: 
C DAISO 
C 





C Ex1ernal variables - used: 
C ALIN'E C*80 
C 
C External variables - set: 
C NTOKE 
C TOKEN (ntokex) 










commonltokenlntoke, token(ntokex), toklen(ntokex ),irefind 
data ifirst/]/ 











C Find the first and last non-delimitors 
C 
C********************************************************************** 










ich=ichar( al ine(icol :icol» 
if(ich.ne.9.and,ich.ne.32.and.ich.ne.61.and.ich.ne.44)go 






C The statement is blank. Rcturn 
C 
C********************************************************************** 











C A if you run out of characters, package those you have into 
C a type 2 token 
C 
C********************************************************************** 
if(aline(icol:icol).eq.'!')go to 30 
ntoke=ntoke+ I 
toklen(ntoke )=iend-icol+ 1 
token(ntoke)=aline(icol:iend) 





C The delimitors are blank, comma, =, and TAB 
C 
C********************************************************************** 
if(ich.eq. 9 .or.ich.eq.32.or.ich.eq.61.or.ich.eq.44 )then 
C********************************************************************** 
C 
C 2. Package the previous characters (if there are any) into 
C a type 2 token 
C 
C********************************************************************** 
if(icoJ .ne.ic )then 
if(aline(icol:icol).eq.'I ')go to 30 
ntoke=ntoke+ 1 
70 















C 3. Find the next non-blank and set as I COL 
C 
C********************************************************************** 
do iool=ic+ l,iend 
C********************************************************************** 
C 










C B. If you run out of characters~ return 
C 
C********************************************************************** 




C Keep collecting characters 
C 
C********************************************************************** 








C Module name: 
C LENG 
C 
































9010 format(!6x,'What is the OORT flux ou','tput file name?'/) 
read(*, '( a60Y)file 1 
open(3 ,file===file l,status='old' ,form='unfonnatted') 
open( 1 ,file==='dortread.out',status='Wlknown' ,form='formatted') 










read(3)hname,(huse(i),i= 1 ,2),ivers 
write(I,902 O)hname, (huse(i),i= 1,2 ),ivers 
9020 format(12x,'FiJe name ==> ',a8l2x,'User identification ==> ',a6, 
*a6!9x,'File version ==> ',i6) 
C*********************************************************************** 
C 









9030 format(!8x,'Date ==> ',a8/8x,'User ==> ',a8/6x,'Charge ==> ',a8! 
*8x:Case ==> ',a8/8x,'Time ==> ',a8111x:Title ==>'l2x,a6,a6,a6, 
*a6,a6,a6,a6,a6,a6,a6,a6,a41) 
9040 formatC!',8x,'date ',a8f!',8x,'user ==> "a8!'!',6x, 
*'cbarge ==> ',as!'f',Sx,'case ==> ',as!'!',Sx,'time ==> ',as!'!'! 











write( 1 ,9050)igm,neutjm,lm,ima,mma,ism,imsism,isbt,iter 
write(2,9060)igm,neutjm,lm,ima,mma,ism,imsism,isbt,iter 
9050 format(21x,'No. of energy groups ==>',lx,i6123x, 
*'Last neutron group ==> ',i6120x,'Number of J intervals ==','>', 
*i6/7x,'Maximum length of moment',lx,'expansion ==> "i6!20x, 
*'Number of I intervals ==', '> ',i6/12x, 
73 
*'Number of boundary direc':tions ==> ',i6116x, 
*'Number of I-boundary set','s ==> "i6114x, 
*'Total number ofI-inteN','als ==> ',i6/14x, 
*'J-set for system boundar','ies ==> ',i6I2x, 
*IOnter iteration no. when',lx,'fluxes written ==> ',i6) 
9060 format('!'/'!',21x,'no. of energy groups ==>',1~i6f!',23~ 
*'last neutron group ==> ',i6f!',20~'number ofj inteNals ==', 
*1> ',i6f!',7x,'maximum length of moment', l~'expansion ==> ',361 
*'!',20x,'number of j intervals ==','> ',i6f!'J2~ 
*'number of boundary direc','tions ==> ',i6f!',16~ 
*'number ofi-boundary set','s ==> ',i6f!',14~ 
*'total number of i-inteN','als ==> ',i6f!',14~ 
*'i-set for system boundar','ies => ',i6/'!',2~ 
*'outer iteration no. when'Jx,'lluxes written ==> ',i6) 
write(2,9070)igm,neutjm,mma 
9070 format(/'!'/'! IGM is number of energ','y groups'f!',2x, 
*'MMA is number of angles'/'!'/lx:igm = ',i511~ 









parameter(ncscrx= 1 0000) 
character* 1 zca 
commonlscrchlnscr,za(nscrx),izzz1 ,izzzm 
commonlcscrchlncser ,zca( ncserx),i7zzem 




kimbis=iale8«ism), 'imbis I) 
kiset=ialc8( (jm)/iset I) 
kz=iale8«(jm+I),'z ') 
kr=iale8«3000)*(ism),'r ') 










real z(*),r(3000, *) 




C Read FILE INTEGER PARAMETERS 








do 10 ig=l,igm 
if(lmbig(ig). gt. I mbigx)lmbigx= I mbig(i g) 
10 continue 
imbisx=O 




9010 format(2x:nr = ',i5) 
C*********************************************************************** 
C * 
C Read FILE REAL PARAMETERS * 
C * 
C*********************************************************************** 
read(3)(z(j)j= Ijm+ 1 ),«r(i,is),i= 1 ,imbis(is)+ 1),is= l,ism),( 
*ener,ig= 1 ,igm),emin,cneut,ev,devdk,efik,powcI,(dumrl,i=1,13) 
writc(2,9020)(z(i),i= 1 jm+ 1) 
9020 format(lx,'z ='/(Ix.,Opf9.4, lx.,Opf9.4, lx.,Opf9.4, lx.,Opf9.4, Ix., 
*Opf9.4, Ix» 
write(2,9030)(r(i,isbt),i= 1 ,imbis(isbt)+]) 
9030 format(lx,'r ='/(lx.,Opf9.4, lx.,Opf9.4, Ix,Opf9.4, Ix.,Opf9.4, Ix., 
*Opf9.4, Ix» 
write(* ,9040) 
9040 format(/3x,'What is the input file t','hat contains the (r,z) p" 
*Ioints desired?'/) 
read(*, '(a60Y)file 1 
call daiso( fiI e 1, 1 , 10000) 







subroutine rdflux(igmjm,imbisx.,imbis,iset,mma, is~neut,r,z, 
* ndes) 
parameter(nscrx= 300000) 
parameter(ncscrx= 1 0000) 
character* I zca 





kflurn=ialc8( (imbisx)*(jm)*(igm), 'flurn ') 
kdose=ialc8( (imbisx)*(jm)*(3 ),'dose ') 
kdneut=ialc8«igm),'dneut ') 
75 
kfdose=ialc8( (igm), '[dose ') 
kden=ialc8( (imbisx)*(im):. 'den I) 

















real flum(imbisxjm, *),dose(imbisxjm, *) 








call daisr('pointsl,0 ,ndes*2,points, I) 
do ]0 i=l,ndes 
rdes(i)=points(2*i-l ) 
zdes(i)= poi nts(2* i) 
10 continue 



















print*: What group do you want?' 
read(*, '(bn,i] O)')igdes 




















do 90 ig= l,igm 





do 60 i=l,ims 
flum(ij,ig)=llum(ij,ig)*fact 
60 continue 











write(2,9030)(imbis(iset(j) )j= Ijrn) 
9030 format(,!'p!.,3x,'Scalar dose in format'I'!'I'!',6x, 
*'( (dose(ij),i= I ,imbis(j)', ')j= 1 jm)'I'! 'I'! 1,6x, 
*'where the IMBIS are the ','number of I nodes'I'!',8x, 
*'per J level'l'f'I'!"4x,'Here are the IMBIS value','s -'1'!'/5x, 
*'imbis ='/( lx,i4, lx,i4, lx,i4, lx,i4, lx,i4, lx,i4, 1 x,i4, lx,i4, I x,i4, 
*lx,i4,lx» 
write(2,9040) 




write(2,90 50)zmi<L ( dose(ij, 1 ),i= l,imbis(iset(j») 
1 00 continue 
9050 formatC!',2x,'Height ',Opfl2.5/(lx,2pel1.4,lx,2peI1.4,lx, 
*2pel 1.4,1x.2pel 1.4, 1x.2pell.4» 
write(2,9060) 
9060 fonnat('!'!,!"3x,'Gamma scalar doses -'f!'/2x,'!Ldose =') 
do 110 j=ljm 
zmid=O.S*(zG)+zG+ I» 











do 120 i= 1 ,imbis(iset(j» 














do 210 id=l,ndes 
write(* ,9070 )i<Lrdes(id),zdes( id) 
9070 format(!'========================', '========================', 










if(rdes(id).lt.r( 1 ).or.rdes(id).gt.r(nr+ 1 »then 
write(* ,9080)rdes(id),r( 1 ),r(nr+ I) 
9080 format(/2x,'Listen, you dwmny!',3x,'The desired R point, ., 
* Opf9.S/4x,'is outside the data rang','e ==> ("Opf9.S,', " 
* Opf7.3,')'I/Sx,'Ignoring that poin!...'1) 
go to 200 
endif 
if(zdes(id).lt.z(I).or.zdes(id).gt.z(nz+ 1»then 
write(* ,9090)zdes(id}.z( 1 ),z(nz+ I) 
9090 fonnat(/2x,'Listen, you dummy!"3x,'The desired Z point, .. 
* Opf9.5/4x:is outside the data rang','e ==> C,OpJ'J.S:, .. 
* Opf7.3:)'IISx,'Ignoring that point... 'I) 
go to 200 
endif 
do 140 ir=1,nr 




do 160 iz=I,nz 
if(zdes(id}.lt.z(iz+ 1»go to 170 
160 continue 
170 j=iz 
write(* .,9100 )ij 
















do ]90 ig=I,igm 
perc=fdose(ig)/tdos* 100. 
if(perc.gt.0.)write(*,9120)ig,flum(ij,ig),fdose(ig),perc 
9110 format(l9x,'Group"5x, 'Flux', I Ox/Dose', 9x., '%'/9x, 
* '===== ========== , '========== ======') 













print*: What do you want the .PS dos','e file to be'll 
read(*, '(a30)'}fiJe 







do 230 i= I ,nr 












parameter(ncscrx= 1 0000) 
character* 1 zca 
common/scrch/nscr,za(nscrx),izzzl,izzzm 




kcolor=ialc8«nx) * (ny),'color I) 










real color(nx, *) 
real xO(nxO+ 1),yO(nyO+ 1) 








do 20 j=l,ny 
do 10 i=l,fiX 







do 40 j=l,ny 
do 30 i=l,nx 






do 50 i=l,nx 
frac=(den(ij)-wtmin)/(\\'tmax-wtmin) 












call drbegin(xil(l),yO(l),xil(nxO+ l),yO(nyO+ l),title,file) 
C*********************************************************************** 
C 






can drthick(. 001) 
call drtype('dasbed') 
do 80 j=l,ny 
do 70 i=l,fl.x 












call drbox(xO(l),yO(l),xil(nxO+ 1),yO(nyO+ 1» 
C*********************************************************************** 
C 







do 100 i=l,nxO 
do 90 j= 1,nyO 
ij=nyO+l-j 
call drbox(xO(i),yO(j),xO(i+ 1 ),yO(j+ 1» 
90 continue 
1 00 continue 
C*********************************************************************** 
C 














cbaracter* 12 avar 
paramete r(nscrx= 3 000(0) 
parame1er(ncscrx= 1 0000) 













9010 format(31h No more REAUINT scratch room.,Th Var ,a,6h Leng, 











character* 1 zea 





















character* 1 zea 
common/scrchlnscr,za(nscrx),izzzl,izzzm 
common/cscrchlncscr ,zea( ncscrx),izzzcm 
ratio 1 =(izzzm * I. )/(nscrx* 1.)* 100. 
ratio2=(izzzcm* l.)/(ncscrx* L)* I 00. 
write{* ,9010 )izzzm,nscrx,ratio I 
9010 format{/ITh OORTREAD used ,ilO,8h out of ,il0, 
*25h real/integer variables (,f8.3,2h%)) 
82 
wrilC(* ,9020)izzzcm,ncsc~ratio2 







character*8 date, user, charge, case, time 
charactcr*8 titl(12) 












open(3 ,file=file 1 ,status='old' ,form='unformatted') 
open( 1 ,file='temp9 .out',status='unknown' ,form='formatted') 











read(3)hnarne,(huse(i),i= 1 ,2),ivers 
write( 4 )hname,(buse(i),i= 1,2),ivers 
write(l,9020)hname,(huse(i),i=1,2),ivers 
writc(* ,9020)hname, (huse(i), i= 1,2),ivers 
9020 format(12x,'File name ==> ',a812x.,'User identification ==> ',a6, 
*a6/9x,'File version ==> ',i21) 
C*********************************************************************** 
C 











write(* ,9040)date,user,charge,case,time,(titl(i),i= 1,7) 
9030 format(/8x,'Date ==> "a8/8x,'User ==> ',a8/6x,'Charge ==> "a81 
*8x,'Case ==> ',a8/8x,'Time ==> ',a8//1x,'Title ==>'/2x,a6,a6,a6, 
*a6,a6,a6,a6,a6,a6,a6,a6,a41) 
9040 formatCf,,8x,'date ==> "a81'!',8x,'uscr ==> \a81'!',6x, 
*'charge => "a8/'!"8x,'case ==> "a8!,!"8x,'time ==> ',a8!,!11 













write(2, 9060)igmjm,ima,mma,nintsr ,njl1tsr 
9050 format(21x,'No. of energy groups ==>',lx,i6/20x, 
*'Number of J intervals ==','> ',i6/20x, 
*'Number of I intervals ==':> ',i6/12x, 
*'Numberofboundary direc':tions ==> ',i6113x, 
*'Number of I-boundary sou','rces ==> "i6/13x, 
*'Number of J-boundary sou','rces ==> "i6) 
9060 format('!',2Ix,'No. of energy groups ==>', lx,i6I'f',20x, 
*'Number of J intervals ==','> ',i6/'!',20x, 
*INumber of I intervals =="'> ',i6/'f,,12x, 
*'Number of boundary direc','tions ==> ',i61'!',13x, 
*'Number of I-boundary sou','rces ==> ',i6f!',13x, 
*'Number of J-boundary sou','rees ==> ',i6) 
CALL DAISO('readflux.inp', 1, 10000) 




















character* 1 zca 
common!scrchlnscr,za(nscrx),izzzl,iz:zzm 
common!cscrchlncscr,zca( ncscrx),izzzcm 
data ifirstJ 11 
nscrO=nscr 
ncscrO=ncscr 
kz=ialc8«(jm+ l),'z ') 
krold=ialc8«101),'rold ') 
kmew=ialc8«nrnew+ 1 ),'mew ') 
kfluxold=ialc8( (mma)*( 100), ':fluxold ') 
kfluxnew=ialc8«mma)*( nmew),'fluxnew ') 
call zdoit 
*(igm,ismjrn,mma,ima,nrold,nrnew, 

























real fluxold(mma, *);fluxnew(mma, *) 
character*60 file 1 
















CALL DAISR('£Old',O,IOl ,rold, 1) 
do 5001 i=I,IOI 
print *,' £old "i,rold(i) 
5001 CONTINUE 
CALL DAISR(,rnew',O,nmew+l,rnew,l) 
do 5002 i= l,nmew+ 1 




C R~d~EnnEGERPARAMETE~ * 






write(* ,541 )zO 
541 format(17x,'Boundary source taken at',lx,'z = ',0pf8.3) 
do 5003 ig= l,igm 
read(3)((fluxold(j,i)j= l,mma),i= 1 ,nrold) 
c write(*,'(i5,lx,fl5.2,eI5.8),)(i,0.5*(rold(i)+rold(i+l», 
c *fluxold(mma,i),i=l,nrold) 
c Now mix them 
do 5004 j=] ,nrold 
jf(rold(j).gt.mew(l»go to 31 
5004 CONTINUE 
31 j=j-l 
do 5005 i=l,nrnew 




c print *,' j = 'j 
do 5007 j= 1 ,nmew 
c print *,' For i = ',i 
nnin=rnew(i) 
33 rmax=rold(j+ 1) 
c print *: Is rnew(i+l) > nnax ',rnew(i+l),rmax 
if(mew(i+ 1 ).It.rmax)nllax=mew(i+]) 
frae=(rmax-rmin)/(mew(i+ l)-rnew(i» 
c print *,' frae is now ',frae 
do 5008 k= l,mma 
fluxnewCki)=fluxnewCk,i)+frac*fluxold(kj) 
5008 CONTINUE 
c print *,' old flux is now "fluxold(mmaj) 
c print *,' new flux is now ',fluxnew(mma,i) 
if(rmax.eq.mew(i+ I »then 
c print *,' Go on to ne:x1 i' 




if(j.gt.nrold)go to 41 
c print *,' Go to next j' 
rm.in=rmax 









c This writes the gamma groups as zeroes 
do 5009 ig= 1,84-igm 
write(4)«zcroj= 1 ,mma),i= 1 ,nme'w) 
5009 CONTINUE 










character* 1 zca 






kflum=ialc8( (imbisx)*(jm)*(igm), 'flum ') 
kdosc=ialc8«imbisx)*(jm)*(3):dose ') 
kdncut=ialc8( (igm), 'dneut ') 
kfdose=ialc8( (igm), 'fdose ') 
kdcn=ialc8«imbisx)*(jm):den ') 
kzdes=ialc8( (ndes) , 'zdes ') 
krdes=ialc8«ndes):rdes ') 




* (igmjm,imbisx, imbis,iset,mma,isbt, ncut, r,z, 
* ndes, 
*Za(kflum),za(kdose),za(kdneut),za(kfdose),za(kdcn) ,za(kzdes) , 









real flum(imbisxjm, *),dosc(imbisxjm, *) 








CALL DAlSR('points' ,0,ndes*2,points, 1) 



















9010 format(/3x,'What is the file name fol,'r the dose response func', 
*ltions?'1) 
read(* ,'(a60)')filel 
if(file I. ne. ")then 
CALLDCLEAR 
CALL DAISO(filel,l, 10000) 
CALL DAISRCdIf ,O,igm,dneut, 1) 
else 
print*: What group do you want?' 
read(*,'(bn,iIO)')igdes 





do 5013 i=I,imbisx 

















do 5015 ig=l,igm 
print*,. Group "ig 
do 5016 j=ljrn 
is=iset(j) 
ims=irnbis(is) 
read(3)(flum(ij,ig),i= 1 ,ims) 
do 5017 i=l,ims 
flum(ij,ig)=fium(ij,ig)* fact 
5017 CONTINUE 
do 5018 i=1 ,ims 
if(igJe.neut)then 



















9030 formatC!'I'!,,3x,'Scalar dose in formatl/ltll't"6~ 
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*'( (dose(ij),i= 1 ,irnbis(j)', ')j= 1 jm)'l'! '1'!',6x, 
*'where the IMBIS are the ':number of I nodes'I'!',8x, 
*'per J level'P!'/'!,,4x,'Here are the IMBIS valuc','s -'1'!'/5x, 
*'imbis ='/( IX,i4, I x,i4, I x,i4, lx,i4, IX,i4, lx,i4, IX,i4, lx,i4, I x,i4, 
*lx,i4,lx» 
write(2,9040) 
9040 format(,!'P!,,3x, 'Neutron scalar doses -'I'!'/2x,'n_dose =') 
do 5019 j=ljm 
zmid=O.5* (z (j)+z(j+ I» 
write(2,90 5 O)zmid,(dosc(ij, l),i=l,imbis(isel(j)) . 
5019 CONTINUE 
9050 format(,!,,2x,'Height ',Opfl2.5/(lx,2pcl 1.4,1 x,2pe I 1.4, lx, 
*2pell.4, 1x,2pel1.4, 1x,2pell.4» 
write(2,9060) 
9060 format(,!'P!',3x,'Gamma scalar doses -'I'!'/2x,'g_dose =') 












do 5021 j= ljm 
do 5022 i=l,imbis(iset(j» 














do 5023 id=l~ndes 
write(* ,9070)i~rdes(id),zdes(id) 
9070 fOl1llat(f!=======================', '========================', 











if(rdes(id).It.r( 1 ).or.rdes(id).gt.r(nr+ 1 »then 
write(* ,9080)rdes(id),r( 1 ),r(nr+ 1) 
9080 fOl1llat(/2x,'Listen, you dummy!\3x,IThe desired R point, I, 
*Opf9.5/4x,'is outside the data rang','e ==> C,Opf9.S,', I, 
*Opf7.3,')'1I5x,IIgnoring that JX)int...'f) 
go to 30 
endif 
if(zdes(id).It.z( 1 ).or.zdes(id).gt.z(nz+ 1 »thell 
write(* ,9090)zdes(id)~z(1),z(nz+ 1) 
9090 fOl1llat(/2x,'Listen, you dummy!',3x,'The desired Z point, ., 
*Opf9.5/4x,'is outside the data rang','e ==> (',Opf9.S,', I, 
*Opf7.3,')'1I5x,'Ignoring that JX)int.. .. f) 
go to 30 
endif 
do 5024 ir=1,nr 
if( rdes(id) Jt.r(i r+ 1) )go to 10 
5024 CONTINUE 
10 i=ir 
do S025 iz= I ,nz 
if(zdes(id).1t.z(iz+ l»go to 20 
502S CONTINUE 
20 j=iz 
write(* ,91 OO)ij 

















do 5027 ig= 1 ,igm 
perc=fdose(ig)/tdos* 100. 
if(perc.gt.O.)write(* ,9120)ig,flum(ij.ig),fdose(ig),pcrc 
9110 fonnat(/9x,'Group',5x,IFlux', 1 Ox/Dose,,9x, '%'/9x , 













print* ->' What do you want the .PS dos','e file to be'l' 
read(*, '(a30)I)file 







do 5028 i= 1 ,nr 
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C Module name: 
C MAKEPS 
C 
C Called modules: 
C DRBEGIN DRTHICK DRTYPE DRFBOX DRBOX DREND LENG 
C 
C Called by: 
C DETERM DOlT 
C 
C External variables - used: 
C DEN (nx,ny) R*4 
C FILE C*80 
C INORM 1*4 
C NX 1*4 
C NXO 1*4 
C NY 1*4 





character* 1 zca 

















real color(nx, *) 
real xO(nxO+ I ),yO(nyO+ 1) 











do 5030 j= 1,ny 
do 5031 i=l,lLx 








do 5032 j= 1 ,ny 
do 5033 i=l,nx 




if(\\1max.le. wtmin)wtmax=wtmin+ 1. 
do 5034 j=l,ny 
do 5035 i=l,nx 
frac=(den(ij)-wtmin)l(wtmax-wtmin) 











call drbegin(xO( 1 ),yO( 1 ),:\.-o(nxO+ 1 ),yO(nyO+ 1 ),title,file) 
C*********************************************************************** 
C 






call drtllick(. 001) 
call drtypeCdashed') 
do 5036 j= 1 ,ny 
do 5037 i=l,nx 










call drbox(xO( 1 ),y0( 1 ),xO(nxO+ 1 ),yO(n),O+ 1)) 
C*********************************************************************** 
C 







do 5038 i=l,nxO 
do 5039 j=l,nyO 
.ii=nyO+ l-j 
















function ialc8( nn,avar) 
character* 12 avar 
parameter(nscrx= 30(000) 
parameter(ncscrx= 1(000) 











if( nser.gt. nserx)then 
\\Tite(* ~9999)avar~nn, nser 
9999 fonnat(31h No more REAUINT scratch room., 






function icalc8( nn) 
parameter(nscrx= 300000) 
parameter(ncscrx= 100(0) 
character* 1 zca 
commonlscrchlnscr ,za( nscrx),izzz 1, iZ7.zm 
commonlcscrch/ncscr,zca( ncscrx),uzzcm 






if( ncscr. gt. ncscrx )then 
write(* ,9999) 










character* 1 zca 
commonlscrchlnscr,za(nscrx)~izzz 1 ,izzzm 
commonlcscrchlncscr ,zca( ncscrx)~izzzcm 
ratio 1 =(izzzm * 1. )/(nscrx* 1.)* 100. 
ratio2=(izzzcm * I. )/(ncscrx* 1.)* I 00. 
write(* ,9999)izzzm,nsc~ratio 1 
9999 fonnat(/l7h TEMP9 used ,ilO,8h out of ,ilO, 
*25h real/integer variables (,f8.3,2h%) 
l\Tite(* ,9998)izzzcm, ncsc~ratio2 
9998 format(l2x,5h and ,ilO,8h out of ,ilO, 






Table 1. Facility Expenses 40 
Clinical Operations 1996 dolla rs 
Labor 4406160 
Benefits and Taxes 1365910 
Clinic Overhead 410879 
Medica) Supplies 88647 
Medical Equipment 26594 
Maintenance 
Total Clinical Operations 6298190 
Clinical Overhead 




Office Supplies 8865 
Travel 2659 
Meetings and Conferences 3546 
Postage and Delivery 3546 
Lega) and Professional 88647 
Consultants 53188 
Licenses and Fees 53188 
Information Systems 17729 
Maintenance 
Employee Development 26594 
Total Clinical Overhead 410879 
Reactor Operations 
SIC Nuclear Engineering 100000 
Operations 
Nuclear Supplies 93080 
Reactor Maintenance 37232 
Reactor Overhead 1195291 
Total Reactor Operations 1425603 
102 
Reactor Overhead 
Facilities Ma'lntenance 17729 




Office SuppHes 3546 
Travel 2659 
Meeting and Conferences 1330 
Postage and Delivery 2659 
Legal and Professional 4432 
Consultants 0 
Licenses and Fees 3546 
Information Systems 4432 
Maintenance 
Employee Development 1773 
Total Reactor Overhead 1195291 
Expenses 
Clinical Operations 6298190 
Clinical Overhead 410879 
Reactor Operations 1425603 
Reactor Overhead 1195291 
Research 4700000 
Total Expenses $14029963 
Personner 
Executive Director 203612 
Oep, Executive Director 179178 
Administrative Director 179178 
Personnel Manager 105878 
Patient SelVices Manager 105878 
Staff (Emp-1) 40722 
Staff (Emp-2J 40722 
Accounting 105878 
Maintenance (Facility) 52125 
Staff (Emp-1) 28506 
Staff (Emp-2) 28506 
Housekeeping 57011 
Staff (Emp-1) 36650 
Staff (Emp-2J 36650 
103 
Maintenance (Grounds) 52125 
Staff (Emp-1) 28506 
Staff (Emp-2) 28506 
Patient QA Director 105878 
Director of Research 203612 
Compound Development 81445 
Diagnostic Systems 81445 
Nuclear Systems 81445 
Medical Sys. and Prac. 81445 
Director of Reactor 179178 
Operations 
Nuclear QA Manager 105878 
Reactor Operator (1) 81445 
Reactor Operator (2) 81445 
Reactor Operator (3) 81445 
Staff (1) 52125 
Staff (2) 52125 
Director of Therapy 203612 
Chief of Nursing 154745 
Nursing Staff 195467 
Therapy Scheduler 52125 
Chief of Services 0 
Neurosurgery 407224 
Thoracic Surgery 407224 
Radiology 407224 
Total Personnel Costs 4406163 
Primary Brain Tumors 
Telemedicine Software 1800 
linkage 1200 
Prequalification 
MRI (regular) 18000 
MRI (boron) 42000 
PET (boron) 48000 
Neurosurgery 
Operating Theater 300000 
Recovery 60000 





Total Primary Brain Tumor Cost 770892 
104 
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